U.S. patent application number 16/877126 was filed with the patent office on 2020-09-10 for reduced sodium food products.
The applicant listed for this patent is General Mills, Inc.. Invention is credited to Olaf Gruess, Joachim Hans, Lars Ole Haustedt, Andreas Hochheimer, Michael Krohn, Jens-Peter Muller, Christine M. Nowakowski, Suzanne Denise Pecore, Candace Michelle Rathjen-Nowak, Lia Scarabottolo, Karsten Siems, Bernhard H. Van Lengerich.
Application Number | 20200281236 16/877126 |
Document ID | / |
Family ID | 1000004843087 |
Filed Date | 2020-09-10 |
View All Diagrams
United States Patent
Application |
20200281236 |
Kind Code |
A1 |
Van Lengerich; Bernhard H. ;
et al. |
September 10, 2020 |
REDUCED SODIUM FOOD PRODUCTS
Abstract
Naturally-derived compounds having various structures elicit the
perception of salty taste, enhance the perception of salty taste of
a salt, or act at one or more sodium channels. Food products may
include such naturally-derived compounds, which may be used to
reduce the sodium content, while imparting a similar level of
saltiness.
Inventors: |
Van Lengerich; Bernhard H.;
(Plymouth, MN) ; Gruess; Olaf; (Maple Grove,
MN) ; Hans; Joachim; (Holzminden, DE) ;
Haustedt; Lars Ole; (Potsdam, DE) ; Hochheimer;
Andreas; (Regensburg, DE) ; Krohn; Michael;
(Lorsch, DE) ; Muller; Jens-Peter; (Berlin,
DE) ; Nowakowski; Christine M.; (Plymouth, MN)
; Pecore; Suzanne Denise; (Pasadena, CA) ;
Rathjen-Nowak; Candace Michelle; (St. Michael, MN) ;
Scarabottolo; Lia; (Peschiera Borromeo, IT) ; Siems;
Karsten; (Michendorf, DE) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
General Mills, Inc. |
Minneapolis |
MN |
US |
|
|
Family ID: |
1000004843087 |
Appl. No.: |
16/877126 |
Filed: |
May 18, 2020 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
16197550 |
Nov 21, 2018 |
|
|
|
16877126 |
|
|
|
|
14820891 |
Aug 7, 2015 |
10159268 |
|
|
16197550 |
|
|
|
|
PCT/US2014/015230 |
Feb 7, 2014 |
|
|
|
14820891 |
|
|
|
|
PCT/US2014/015192 |
Feb 7, 2014 |
|
|
|
14820891 |
|
|
|
|
PCT/US2014/015200 |
Feb 7, 2014 |
|
|
|
PCT/US2014/015192 |
|
|
|
|
PCT/US2014/015207 |
Feb 7, 2014 |
|
|
|
PCT/US2014/015200 |
|
|
|
|
PCT/US2014/015211 |
Feb 7, 2014 |
|
|
|
PCT/US2014/015207 |
|
|
|
|
PCT/US2014/015216 |
Feb 7, 2014 |
|
|
|
PCT/US2014/015211 |
|
|
|
|
PCT/US2014/015220 |
Feb 7, 2014 |
|
|
|
PCT/US2014/015216 |
|
|
|
|
PCT/US2014/015227 |
Feb 7, 2014 |
|
|
|
PCT/US2014/015220 |
|
|
|
|
PCT/US2014/015227 |
Feb 7, 2014 |
|
|
|
PCT/US2014/015227 |
|
|
|
|
PCT/US2014/015239 |
Feb 7, 2014 |
|
|
|
PCT/US2014/015227 |
|
|
|
|
PCT/US2014/015240 |
Feb 7, 2014 |
|
|
|
PCT/US2014/015239 |
|
|
|
|
PCT/US2014/015244 |
Feb 7, 2014 |
|
|
|
PCT/US2014/015240 |
|
|
|
|
61762781 |
Feb 8, 2013 |
|
|
|
61762792 |
Feb 8, 2013 |
|
|
|
61762798 |
Feb 8, 2013 |
|
|
|
61762804 |
Feb 8, 2013 |
|
|
|
61763244 |
Feb 11, 2013 |
|
|
|
61763274 |
Feb 11, 2013 |
|
|
|
61763300 |
Feb 11, 2013 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A23L 27/45 20160801;
A23L 7/117 20160801; A23L 23/00 20160801; A23V 2002/00 20130101;
A23L 27/40 20160801 |
International
Class: |
A23L 7/117 20060101
A23L007/117; A23L 27/40 20060101 A23L027/40; A23L 23/00 20060101
A23L023/00 |
Claims
1-78. (canceled)
79. A food product comprising: a first ingredient; a salt that
imparts a salty taste; and a compound having the following
structure: ##STR00205## where: R.sup.1 is H or C.sub.1-C.sub.10
alkyl; R.sup.2 is H or C.sub.1-C.sub.3 alkyl; X is CHOR.sup.3 or
C.dbd.O; R.sup.3 is H, C.sub.1-C.sub.3 alkyl, or ##STR00206##
R.sup.4 is H or C.sub.1-C.sub.3 alkyl; Y is CR.sup.5.dbd.CH or
CHR.sup.5--CH.sub.2; R.sup.5 is H, OH, --OCH.sub.3,
--OCH.sub.2CH.sub.3, --O--OCH.sub.2CH.sub.2CH.sub.3, or
##STR00207## and R.sup.6 is H or C.sub.1-C.sub.3 alkyl, wherein the
compound of formula A is present in the food product in an amount
sufficient to enhance a perception of saltiness of the food
product, and wherein the compound of formula A is isolated or
purified before being included in the food product.
80. The food product of claim 79, wherein R.sup.1 is
C.sub.2-C.sub.8 alkyl.
81. The food product of claim 79, wherein R.sup.2 is H.
82. The food product of claim 79, wherein X is C.dbd.O or
##STR00208## where R4 is CH.sub.3.
83. The food product of claim 79, wherein Y is CR.sup.5.dbd.CH and
R.sup.5 is H.
84. The food product of claim 79, wherein Y is CHR.sup.5--CH.sub.2
and R.sup.5 is OH or --OCH.sub.3.
85. The food product of claim 79, wherein R.sup.6 is CH.sub.3.
86. The food product of claim 79, wherein the compound of formula A
is one of the following compounds: ##STR00209## ##STR00210##
87. The food product of claim 79, wherein the compound of formula A
is compound 1.
88. The food product of claim 79, wherein the compound of formula A
is compound 2.
89. The food product of claim 79, wherein the compound of formula A
is compound 3.
90. The food product of claim 79, wherein the compound of formula A
is compound 4.
91. The food product of claim 79, wherein the compound of formula A
is compound 5.
92. The food product of claim 79, wherein the compound of formula A
is compound 6.
93. The food product of claim 79, wherein the compound of formula A
is compound 7.
94. The food product of claim 79, wherein the compound of formula A
is compound 8.
95. The food product of claim 79, wherein the compound of formula A
is compound 9.
96. The food product of claim 79, wherein the compound of formula A
is present in the food product from 0.01 to 2 percent by weight.
Description
RELATED APPLICATIONS
[0001] This application claims the benefit of each of the following
Provisional Patent Applications: US 61/762,781, filed on Feb. 8,
2013; US 61/762,792, filed on Feb. 8, 2013; US 61/762,798, filed on
Feb. 8, 2013; US 61/762,804, filed on Feb. 8, 2013; U.S.
61/763,244, filed on Feb. 11, 2013; US 61/763,274, filed on Feb.
11, 2013; and US 61/763,300, filed on Feb. 11, 2013. Each of the
above-referenced US Provisional Patent Applications is hereby
incorporated herein by reference in its respective entirety to the
extent that it does not conflict with the disclosure presented
herein.
FIELD
[0002] This disclosure generally relates to, among other things,
food products having a compound that modifies or enhances the taste
of the food product, for example, the saltiness of the food
product.
BACKGROUND
[0003] Sodium chloride, ordinary table salt, is the prototypical
compound for eliciting the perception of salty taste. However,
attempts to reduce sodium consumption have led investigators to
find suitable substitutes for sodium chloride or to reduce sodium
chloride amounts, without sacrificing salty taste.
[0004] Salts can elicit complex tastes, including mixtures of
sweet, bitter, sour, umami, and salty perceptual components. It is
believed that the cations of salts impart the perceptual taste
component, while the anions, in addition to contributing to tastes
of their own, modify the perception of the taste of the cations. By
way of example, sodium and lithium are believed to impart only
salty tastes, while potassium and other alkaline earth cations
produce both salty and bitter tastes. Among the anions commonly
found in foods, the chloride ion is considered to be the least
inhibitory to the salty taste, while the citrate anion is more
inhibitory.
[0005] Many attempts have been made to provide salty tasting
compositions as a substitute for table salt which will give the
same or a similar seasoning effect and which are comprised of
substantially reduced quantities of sodium chloride. To this end,
potassium chloride, ammonium chloride, and similar compounds have
been suggested. The use of such salts, and combinations of such
salts, leaves much to be desired as to taste. None of them
individually or in combination positively affects other taste
modalities and tastes like sodium chloride. Each alone has a
disagreeable taste, as do mixtures of such salts. For example,
potassium chloride has a strong aftertaste that is characterized as
"bitter" by most people. Ammonium chloride also has a bitter
aftertaste.
SUMMARY
[0006] This disclosure describes, among other things, compounds
that elicit or enhance the perception of salty taste, or another
taste associated with consumption of sodium chloride or other
salts, or that interact with a receptor or ion channel associated
with the perception of salty taste or another complex taste
associated with consumption of sodium chloride or other salts. In
embodiments, the compounds are naturally derived taste modulating
compounds used as ingredients in food products to elicit or enhance
perception of salty taste. In embodiments, the food products
contain lower amounts of sodium than normal.
[0007] As described herein, a number of derived compounds were
screened for their ability to modulate activity of a sodium channel
in vitro. Many of the identified compounds were found to enhance
the saltiness of a composition containing sodium chloride.
[0008] One or more embodiments of the compounds, compositions, food
products or methods described herein provide one or more advantages
over prior compounds, compositions, food products or methods. For
example, food products that include one or more taste modulating or
salty taste modulating compounds described herein may have lower
sodium content relative to food products that do not include such
taste modulating or salty compounds while imparting a similar level
of saltiness. This and other advantages will be readily understood
from the following detailed description.
BRIEF DESCRIPTION OF THE DRAWINGS
[0009] FIG. 1 is a table that provides results of DAP score testing
regarding the perception of saltiness of various combinations of
compounds in sodium chloride solution.
[0010] FIG. 2 is a table that provides results of DAP score testing
regarding the perception of saltiness of various combinations of
compounds in combination in broth solution.
DETAILED DESCRIPTION
[0011] This disclosure describes, among other things, compounds
that elicit or enhance the perception of salty taste or another
taste associated with consumption of sodium chloride. In
embodiments, the compounds are taste modulating compounds used as
ingredients in food products to elicit or enhance perception of
salty taste. In embodiments, the food products are food products
that contain reduced amounts of sodium, while imparting a salty
taste typically associated with higher amounts of sodium.
[0012] In embodiments, a food product includes (i) a taste
modulating or salty taste modulating compound, or derivatives
thereof, or (ii) a composition that comprises a taste modulating or
salty taste modulating compound, or derivatives thereof. The taste
modulating, or salty taste modulating compound may be derived from
a natural product, may be synthesized, or may be isolated or
purified.
[0013] As used herein, a "food product" is a food in a form that
does not exist in nature. In embodiments, a food product includes
at least two edible ingredients that do not exist together in
nature. A "food" is a nutritious substance that animals, including
humans, pets and livestock, eat or drink. A "nutritious substance"
is a macronutrient such as a fat, carbohydrate or protein, or a
micronutrient such as an essential or non-essential vitamin or
mineral.
[0014] One or more taste modulating or salty taste modulating
compounds described herein or derivatives thereof, alone or in
combination, may be incorporated into a food product. The one or
more compounds may elicit a perception of saltiness when the food
product is consumed. In embodiments, the one or more compounds are
included in a food product that contains a salt that imparts a
salty taste. Preferably, at least one of the one or more compounds
is a taste modulating compound or salty taste modulating
compound.
[0015] In embodiments, a food product includes an ingredient, a
salt that imparts a salty taste, and a taste modulating or salty
taste modulating compound. The ingredient may be a nutritious
ingredient; that is, an ingredient that is a nutritious substance.
The taste modulating or salty taste modulating compound may be
present in the food product in an amount sufficient to enhance the
salty taste of the food product. In embodiments, the ingredient,
the salt and the taste modulating or salty taste modulating
compound are present in the food product in amounts or
concentrations not found in naturally existing food products, such
as bananas, peppers, avocados, wheat, or the like.
[0016] In embodiments, at least one of the one or more compounds is
a salty taste modulating compound and is present in the food
product in an amount or concentration sufficient to elicit or
enhance the perception of saltiness. In embodiments, the one or
more salty taste modulating compounds are present in the food
product in an amount or concentration sufficient to elicit or
enhance the perception of salty taste such that less salt may be
included in the food product to elicit a similar perception of
saltiness as a substantially similar food product that does not
include the one or more salty taste modulating compounds.
Preferably, the reduced salt food product elicits the same or a
similar perception of saltiness as a substantially similar food
product that does not include the one or more salty taste
modulating compounds.
[0017] In embodiments, the one or more taste modulating or salty
taste modulating compounds are present in a food product in an
amount or concentration sufficient to elicit or enhance the
perception of salty taste such that the amount of sodium may be
reduced by about 10 mg or more per serving relative to a
substantially similar food product that does not have the one or
more taste modulating or salty taste modulating compounds while
having a similar salty taste. In embodiments, the one or more taste
modulating or salty taste modulating compounds are present in a
food product in an amount or concentration sufficient to elicit or
enhance the perception of salty taste such that the amount of
sodium in a serving of a food product may be reduced to about 150
mg or less, more particularly to about 100 mg or less, more
particularly to about 75 mg or less, more particularly to about 25
mg or less, more particularly to about 10 mg or less. By way of
example, it may be desirable to reduce sodium by about 10 mg or
more in cereals or snacks per serving relative to a substantially
similar food product that does not have the one or more taste
modulating or salty taste modulating compounds while having a
similar salty taste. It may be desirable to reduce sodium to about
150 mg or less, more particularly to about 100 mg or less, more
particularly to about 75 mg or less, more particularly to about 25
mg or less, more particularly to about 10 mg or less in cereals or
snacks per serving. For cereal, a typical serving size is 50 grams.
Of course, cereals may have other serving sizes.
[0018] In embodiments, the one or more taste modulating or salty
taste modulating compounds are present in a food product in an
amount or concentration sufficient to elicit or enhance the
perception of salty taste such that the amount of sodium may be
reduced by about 20 mg or more per serving relative to a
substantially similar food product that does not have the one or
more taste modulating or salty taste modulating compounds while
having a similar salty taste. In embodiments, the one or more taste
modulating or salty taste modulating compounds are present in a
serving of a food product in an amount or concentration sufficient
to elicit or enhance the perception of salty taste such that the
amount of sodium may be reduced to about 800 mg or less, more
particularly to about 500 mg or less, more particularly to about
300 mg or less, more particularly to about 100 mg or less, more
particularly to about 20 mg or less. By way of example, it may be
desirable to reduce sodium by about 20 mg or more in meals per
serving. It may be desirable to reduce sodium to about 800 mg or
less, more particularly to about 500 mg or less, more particularly
to about 300 mg or less, more particularly to about 100 mg or less,
more particularly to about 20 mg or less in meals per serving.
[0019] In embodiments, the one or more taste modulating or salty
taste modulating compounds are present in a food product in an
amount or concentration sufficient to elicit or enhance the
perception of salty taste such that the amount of sodium may be
reduced by about 100 mg or more per serving relative to a
substantially similar food product that does not have the one or
more taste modulating or salty taste modulating compounds while
having a similar salty taste. In embodiments, the one or more taste
modulating or salty taste modulating compounds are present in a
serving of a food product in an amount or concentration sufficient
to elicit or enhance the perception of salty taste such that the
amount of sodium may be reduced to about 800 mg or less, more
particularly to about 500 mg or less, more particularly to about
300 mg or less, more particularly to about 200 mg or less, more
particularly to about 100 mg or less relative to a substantially
similar food product that does not have the one or more taste
modulating or salty taste modulating compounds while having a
similar salty taste. By way of example, it may be desirable to
reduce sodium by about 100 mg or more in soups per serving. It may
be desirable to reduce sodium to about 800 mg or less, more
particularly to about 500 mg or less, more particularly to about
300 mg or less, more particularly to about 200 mg or less, more
particularly to about 100 mg or less in soups per serving. For
soup, a typical serving size is 250 grams. Of course, soups may
have other serving sizes.
[0020] Any suitable combination of compounds described herein, or
derivatives thereof, may be included in a food product. In
embodiments, a food product includes a combination of compounds
such that the combination includes at least two structurally
diverse taste modulating or salty taste modulating compounds.
[0021] A food product or composition may include one or more
compounds described herein, or derivatives thereof, in any suitable
concentration. By way of example, a compound described herein, or a
derivate thereof, such as a taste modulating or salty taste
modulating compound may be present in a food product at a
concentration of about 0.01% by weight or greater, about 2% by
weight or less, or from about 0.01% by weight to about 2% by
weight. It will be understood that the concentration of the salt or
salts in the food product may affect the desired concentration of a
taste modulating or salty taste modulating compound. For example,
if more salt is present, less taste modulating or salty taste
modulating compound may be desired. In addition, it will be
understood that the presence of more than one taste modulating or
salty taste modulating compound may affect the desired
concentration of other taste modulating or salty taste modulating
compounds, particularly if the effects of the taste modulating or
salty taste modulating compounds are additive or synergistic.
[0022] Any salt that imparts a salty taste may be present or
incorporated into a food product that contains a bioactive, taste
modulating, or salty taste modulating compound. The most commonly
used salt for food applications is sodium chloride (typically
referred to as common table salt). Other illustrative sources of
sodium salts that may be present of incorporated into a food
product include sodium phosphates, mono sodium glutamate, sodium
nitrite, sodium nitrate, sodium bicarbonate, sodium lactate, sodium
citrate, and sodium stearoyl lactylate. Similar lithium, potassium,
ammonium or other alkali earth salts may be present or included in
addition or as an alternative to one or more sodium salts.
[0023] In embodiments, a food product includes sodium chloride as a
salt that imparts a salty taste. Sodium chloride may be present in
the food product at any suitable amount or concentration. In
embodiments, sodium chloride is present in the food product in an
amount up to about 10.0 weight percent, more particularly, up to
about 5.0 weight percent, even more particularly up to about 1.2
weight percent, or in the range of about 0.017 to about 1.2 weight
percent, or about 0.1 to about 1, or about 0.4 to about 0.6 weight
percent. In embodiments, a food product that includes one or more
bioactive, taste modulating, or salty taste modulating compounds
comprises no more than 0.04 weight percent, no more than 0.1 weight
percent sodium, no more than 0.2 weight percent, no more than 0.25
weight percent sodium, no more than 0.3 weight percent, no more
than 0.4 weight percent, no more than 0.5 weight percent sodium, no
more than 0.75 weight percent sodium, no more than 1 weight percent
sodium, no more than 5 weight percent sodium, or no more than 10
weight percent sodium. It will be understood that a desired weight
percent of sodium may vary depending on the type of food product.
For example, it may be desirable for a seasoning to have a higher
weight percent sodium than a soup or a breakfast cereal. In
embodiments, a food product that includes one or more taste
modulating or salty taste modulating compounds comprises no more
than 100 mg sodium per serving, no more than 250 mg sodium per
serving, no more than 500 mg sodium per serving.
[0024] One or more taste modulating or salty taste modulating
compounds may be utilized in connection with virtually any food
product for which it is desired to elicit or enhance the perception
of a salty taste or other taste associated with consumption of a
salt. The taste modulating or salty taste modulating compounds can
find application for imparting saltiness to beverages or food
dishes or as an ingredient in snack foods or other food products in
which saltiness is desired.
[0025] Examples of food products that may incorporate one or more
taste modulating or salty taste modulating compound include a
confectionary, a gum, a bakery product, an ice cream, a dairy
product, a fruit snack, a chip or crisp, an extruded snack, a
tortilla chip or corn chip, a popcorn, a pretzel, a nut, a snack
bar, a meal replacement, a ready meal, a soup, a pasta, a canned
food, a frozen processed food, a dried processed food, an instant
noodle, a chilled processed food, an oil or fat, a sauce dressing
or condiment, a dip, a pickled product, a seasoning, a baby food, a
spread, a chip or a crisp such as chips or crisps comprising
potato, corn, rice, vegetable (including raw, pickled, cooked and
dried vegetables), a fruit, a grain, a soup, a seasoning, a baked
product such as a ready-to-eat breakfast cereal, hot cereal or
dough, an ice cream such as a frozen yogurt, a dairy products such
as a yogurt or cheese, ready meal, a soup, a pasta, a canned food,
a frozen processed food, a dried processed food, an instant noodle,
or a chilled processed food, a beverage including beverages that
include fiber or protein a meat or a meat substitute, a pet food,
an animal product, a medical food, a nutritional supplement, a
vitamin supplement, and an infant formula product.
[0026] In embodiments, one or more bioactive, taste modulating, or
salty taste modulating compounds are incorporated into a medicinal
or pharmaceutical product, or the like.
[0027] In embodiments, a food product is a processed food product.
Food processing includes the transformation of raw ingredients into
food or transforming forms of food into other forms of food. Food
processing often includes using harvested crops or animal products
to produce marketable products sold to consumers at stores,
restaurants and the like. Processed food products include products
for which additional processing by a consumer occurs after purchase
but prior to consumption (e.g., heating, cooking, baking, or the
like).
[0028] Particularly suitable food products including soup, meal
kits, grain products such as ready-to-eat cereals, snacks, bars and
baked dough, and dairy products such as ice cream, yogurt and
cheese. In some aspects, a bioactive, taste modulating, or salty
taste modulating compound is used to reduce the amount of sodium
salt that is typically included in soups, including (but not
limited to) chicken or poultry broth, chicken- or poultry-based
soups (such as chicken noodle soup), tomato-based soups, and the
like. In some aspects, a taste modulating or salty taste modulating
compound is used to reduce sodium salt in meal kits, such as kits
that include ingredients to be combined with meat to prepare a
meal. Such meal kits can include dried components (such as noodles,
rice, dried potatoes, or the like) and seasoning packages. In some
aspects, a taste modulating or salty taste modulating compound is
used to reduce the sodium chloride that is typically added to a
snack food to enhance its flavor. Exemplary snack foods include
potato chips, corn chips, pretzels, fruit-type snacks, and snack
mixes including any mixes of any of these foods with other
ingredients (such as cereals).
[0029] In some aspects, a taste modulating or salty taste
modulating compound is used to reduce the amount of sodium salt
that is typically included in a ready-to-eat cereal or other
grain-based food products, such as dough, baked goods, grain
snacks, grain bars, or the like. In some aspects, a taste
modulating or salty taste modulating compound is used to reduce the
amount of sodium salt that is typically included in dairy-based
food products, such as fresh or frozen dairy products, which may
include yogurt, ice cream, or the like. In some aspects, a taste
modulating or salty taste modulating compound is used to reduce the
amount of sodium salt that is typically included in packaged meal
food products, such as packaged meals that contain rice, potatoes,
or vegetables, dry packaged meals, frozen packaged meals, or the
like.
[0030] For the purposes of the present disclosure "grain" includes
grain and pseudograin. Examples of food grains include corn;
sorghum; fonio; millet such as pearl millet, proso millet, finger
millet, foxtail millet, Japanese millet, kodo millet and the like;
Job's tears; wheat; rice; rye; barley; oat; triticale; wild rice;
teff; amaranth; quinoa; buckwheat; and the like.
[0031] A taste modulating or salty taste modulating compound can
also be used in connection with soup, broth, sauce (such as basting
sauce), various seasoning sauces, ketchup, dressings, and other
like foods.
[0032] In embodiments, a food product into which a taste modulating
or salty taste modulating compound or composition is included has a
water content of about 30% or more by weight. For example, the food
product may have a water content of about 35% or more, or about 40%
or more by weight. Non-limiting examples of food products that
typically have water contents of about 30% or more by weight
include soups, beverages, batters and dough.
[0033] In embodiments, a food product into which a taste modulating
or salty taste modulating compound or composition is included has a
water content of about 50% or more by weight. For example, the food
product may have a water content of about 60% or more, or about 70%
or more by weight. Non-limiting examples of food products that
typically have water contents of about 50% or more by weight
include soups and beverages. For example, a soup containing a taste
modulating or salty taste modulating compound or composition may
contain from about 50% water by weight to about 90% water by
weight.
[0034] In embodiments, a food product into which a taste modulating
or salty taste modulating composition is included has a water
content of about 20% or less by weight. For example, the food
product may be incorporated into dry food products that having low
water contents. In embodiments, a taste modulating or salty taste
modulating food product is included in a dried for as a seasoning.
In embodiments, the seasoning comprises, consists essentially of,
or consists of one or more taste modulating or salty taste
modulating compounds, one or more carriers, and one or more
salts.
[0035] A taste modulating or salty taste modulating compound can be
employed to elicit the perception of salty taste or enhance the
perceived salt taste of any salts used in food or beverage
products. The preferred salt taste to be elicited or enhanced by
the salty compounds is that of sodium chloride.
[0036] Moreover, a taste modulating or salty taste modulating
compound described herein can be used to elicit or enhance the
perceived salt taste of known salty tasting compounds that may be
used as salt substitutes. Such compounds include amino acids such
as cationic amino acids and low molecular weight peptides such as
dipeptides and tripeptides. Specific examples of these compounds
include arginine hydrochloride, lysine hydrochloride, and
lysine-ornithine hydrochloride. These compounds exhibit a salty
taste but are typically useful only at low concentrations since
they exhibit a bitter flavor at higher concentrations. Ordinarily,
these salt-tasting compounds will be used in concentrations in the
range of about 1 to about 40 mM, or about 10 to about 30 mM. Thus,
it is feasible to reduce the sodium chloride content of a food or
beverage product by first formulating a food or beverage with less
sodium chloride than is necessary to achieve a desired salt taste
and then adding to the food or beverage a taste modulating or salty
taste modulating compound described herein in an amount sufficient
to enhance the salt taste of the salted food or beverage to reach
the desired taste. In addition, sodium chloride content may be
further reduced by substituting a salt-tasting cationic amino acid,
a low molecular eight dipeptide, or mixtures thereof, for at least
a portion of the salt.
[0037] In embodiments, a method includes setting a target salty
taste of a food product, including an amount of a salt that imparts
a salty taste in the food product, where the amount of the salt
does not achieve the target level of salty taste, and including an
amount of a salty taste enhancing compound (or more than one salty
taste enhancing compounds) to achieve the desired salty taste. In
embodiments, a method includes setting a target salty taste of a
food product, including an amount of a salty-taste imparting sodium
salt in the food product that does not achieve the target level of
salty taste, including an amount of a non-sodium salt that imparts
a salty taste and an amount of a salty taste enhancing compound (or
more than one salty taste enhancing compounds) to achieve the
desired salty taste.
[0038] Processing
[0039] A taste modulating or salty taste modulating compound, or
derivative thereof, described herein can be added to food products
in dry or liquid form. For example, a taste modulating or salty
taste modulating compound that is in the liquid form can be
prepared by simply dissolving or suspending the compound in an
appropriate relative amount in an aqueous liquid. Useful aqueous
liquids include water, alcohol-water mixtures, triacetin, propylene
glycol, and triglycerides and other known organic solvents.
Depending upon the concentration of the taste modulating or salty
taste modulating compound, it can be desirable to heat the mixture
to dissolve the compound.
[0040] Taste modulating or salty taste modulating compounds that
exist in a dry state, such as powders or granules, can be prepared
by either mixing or blending the compounds with other components in
the dry state. The dry blending or mixing can be carried out in any
conventional suitable apparatus. In some aspects, the taste
modulating or salty taste modulating compounds described herein can
be prepared into dry compositions by commonly used methods of
granulation from mixtures of the several ingredients, preferably
initially conveniently smaller than forty mesh. Such starting
mixtures can be wetted in known manner, granulated, and their
granulations dried as usual and screened to give a product
approximately the typical size of common table salt, for example,
by taking the fraction passing through the thirty mesh screen and
retained on the forty mesh screen.
[0041] Taste modulating or salty taste modulating compounds that
exist in a dry composition state can be alternatively prepared by
first forming a solution, emulsion or suspension of the compounds
and other individual components, and then extruding or drying the
solution or suspension. The preparation of the solution or
suspension of the components can be carried out as described above
in the context of preparing the liquid flavoring agents. The
thus-prepared solution, emulsion or suspension can then be dried
using any conventional suitable apparatus, such as a rotary drier,
a drum drier, or a fluidized bed drier or spray drier.
[0042] Taste modulating or salty taste modulating compounds
described herein can be prepared by thoroughly mixing the compounds
with other components in the indicated proportions until a suitably
mixed (for example, homogeneous) product is attained.
[0043] Compositions or formulations containing the taste modulating
or salty taste modulating compounds can then be combined with a
food product.
[0044] Perception of Saltiness
[0045] In embodiments, a composition that includes a salty taste
modulating compound is perceived as imparting a quantity of
saltiness equal to a substantially similar composition that does
not include the salty taste modulating compound but that has a
higher concentration of the salt. Preferably, the composition that
includes the salty taste modulating compound imparts a perception
of saltiness equal to the substantially similar composition that
does not have the salty taste modulating compound when the
composition has less salt than the substantially similar
composition (e.g., salt reduced by about 1% or more). For example,
the composition that includes the salty taste modulating compound
may impart a perception of saltiness equal to the substantially
similar composition that does not have the salty compound when the
composition that includes the salty taste modulating compound has a
salt concentration reduced by about 2% or more, about 5% or more,
about 7% or more, about 8% or more, about 9% or more, about 10% or
more, about 11% or more, about 15% or more, about 20% or more,
about 30% or more, about 35% or more, about 40% or more, or about
50% or more, relative to the substantially similar composition. In
embodiments, one or more salty taste modulating compounds may be
present in a food product in an amount sufficient to reduce the
amount of a salt, such as sodium chloride, by about 1% or more,
about 2% or more, about 5% or more, about 7% or more, about 8% or
more, about 10% or more, about 11% or more, about 12% or more,
about 15% or more, about 20% or more, about 22% or more, about 25%
or more, about 30% or more, about 35% or more, about 40% or more,
about 45% or more, about 50% or more, about 55% or more, about 60%
or more, about 65% or more, about 70% or more, about 75% or more,
about 80% or more, about 85% or more, about 90% or more, about 95%
or more, or the like. Preferably, the reduced salt food product
elicits the same or similar perception of saltiness as a
substantially similar food product that does not include the one or
more salty taste modulating compounds.
[0046] Perception of saltiness may be evaluated in any suitable
manner. In embodiments, saltiness is determined by a trained
analytical sensory panel. In embodiments, the trained sensory panel
determines the saltiness of a composition having a salty taste
modulating compound relative to a substantially similar composition
having increased sodium chloride content.
[0047] Sensory panelists may be trained in any suitable manner.
Preferably, the panelists are trained to discern salty taste or
other attributes without reference to liking or acceptability. The
panelists are also preferably trained to accurately quantify salty
taste or other attributes according to an intensity scale. General
information that may be helpful in understanding beneficial
training protocols can be found in, for example, Sensory Evaluation
Techniques, 4.sup.th Ed by Meilgaard M., Civille G. V. and Can B. T
(2007), CRC Press, pages 147-152. Prescreening, selection, and
training of panelists may be occur as described in one or more
standards, such as Hootman R C, Manual 13 MNL13 Manual on
Descriptive Analysis Testing for Sensory Evaluation, ASTM (1992);
STP758 Guidelines for the Selection and Training of Sensory Panel
Members, ASTM (1981); and Munoz A. M and Civille, G. V., MLN13: The
Spectrum Descriptive Analysis Method, ASTM (1992). Preferably
panelists are trained according to the Spectrum Method (Munoz A. M
and Civille, G. V., MLN13: The Spectrum Descriptive Analysis
Method, ASTM 1992).
[0048] Preferably, average scores regarding saltiness from more
than one panelist trained to discern salty taste or other
attributes using the same training are considered in determining
whether a reduced salt food product elicits the same or similar
perception of saltiness as a substantially similar food product
that does not include the one or more salty taste modulating
compounds. For example, a panel may contain three or more trained
panelists, 5 or more trained panelists, 7 or more trained
panelists, 10 or more trained panelists, or the like.
[0049] A taste modulating or a salty taste modulating compound may
be a compound that directly acts to elicit or enhance the
perception of salty taste of a salt or may be a compound that is
converted, when ingested, into a compound that directly acts to
elicit enhance the perception of salty taste of the salt.
[0050] Taste Modulating, and Salty Taste Modulating Compounds
[0051] A variety of naturally-derived compounds were tested in
vitro for their ability to activate or facilitate activation of a
TrpML3 channel, a TrpV1 channel or an ENaC channel.
[0052] The TrpML3 (transient receptor potential cation channel,
mucolipin subfamily, member 3) channel, also known as Mucolipin-3
is a protein that, in humans, is encoded by the MCOLN3 gene. The
TrpV1 (transient receptor potential cation channel subfamily V
member 1) channel, also known as the capsaicin receptor and the
vanilloid receptor 1, is a protein that, in humans, is encoded by
the TrpV1 gene. The ENaC (epithelial sodium channel), also known as
sodium channel non-neuronal 1 (SCNN1) or amiloride sensitive sodium
channel (ASSC) is a membrane-bound ion-channel that is permeable
for Li+-ions, protons and especially Na+-ions.
[0053] Any compound that interacts with one or more of the TrpML3
channel, the TrpV1 channel and the ENaC channel may be useful for
modulating taste or saltiness of a food product into which the
compound is incorporated.
[0054] It is estimated that natural products, extracts, and
isolated compounds that collectively contained about 2,000,000
potential taste modulating or salty taste modulating compounds were
tested for sodium channel activity. About 600 of the 2,000,000
compounds had some level of sodium channel activity. About 300 of
the 600 compounds had an increased threshold level of activity.
Further analysis, including structure based toxicological analysis,
resulted in 99 initial compounds being selected as candidates for
taste modulating or salty taste modulating compounds. Presented
herein are naturally-derived compounds and compound classes that
have been identified as acting at one or more of these channels, or
that otherwise may function as bioactive, taste modulating, or
salty taste modulating compounds.
[0055] A listing of the 99 initially selected compounds (Cmpd), as
well as the common names (where known), Chemical Abstract Service
(CAS) Registry numbers where known (CAS-RN), Sources/Taxons (where
known) from which the compounds were isolated (Source/Taxon) and
common name of the sources (Common Name), is presented in Table 1
below. The structures of the compounds are also presented herein.
To the extent the structures conflict with other information
provided, the structures of the 99 initially selected compounds
should be considered determinative.
TABLE-US-00001 TABLE 1 Information regarding initially selected
compounds Cmpd CAS-RN Common name Source/Taxon Common Name 1
104264-55-3 12-Gingerol Zingiber officinalis Ginger 2 36752-54-2
[10]-Shogaol Zingiber officinalis Ginger 3 143615-75-2
[6]-Gingerdiacetate Zingiber officinalis Ginger 4 555-66-8
6-Shogaol Aframomum meleguata, Grains of paradise; Zingiber
officinalis Ginger 5 39886-76-5 [6]-Gingerol Zingiber officinalis
Ginger 6 53172-04-6 [7]-Paradol Aframomum meleguata, Grains of
paradise; Zingiber officinalis Ginger 7 27113-22-0 [6]-Paradol or
Aframomum meleguata, Grains of paradise; [6]-Gingerone Zingiber
officinalis Ginger 8 626200-64-4 5-methoxy-[6]-Gingerol Aframomum
meleguata, Grains of paradise; Zingiber officinalis Ginger 9
23513-08-8 8-Gingerol Zingiber officinalis Ginger 10 1083195-12-3 a
pentadecatrienyl-1,3-benzenediol Embelia ribes False Black Pepper,
white-flowered Embelia 11 79559-60-7 a 1-Ph-4-hepten-3-one
Kaempferia galanga Kencur, aromatic ginger, sand ginger, cutcherry,
resurrection lily 12 79559-61-8 a 1-Ph-5-OH-3-heptanone Kaempferia
galanga Kencur, aromatic ginger, sand ginger, cutcherry,
resurrection lily 13 205687-01-0 Capsiate Capsiate 14 147030-09-9
Pipersintenamide Piper longum Long pepper, Indian long pepper 15
55038-30-7 Guineensine Piper longum Long pepper, Indian long pepper
16 182056-19-5 Evodia rutaecarpa Evodia fruit 17 15266-38-3
Evocarpine Evodia rutaecarpa Evodia fruit 18 94-62-2 Piperine Piper
longum Long pepper, Indian long pepper 19 52483-20-2 Irisresorcinol
Ardisia silvestris 20 79559-61-8 a 1-Ph-5-OH-3-heptanone Alpinia
officinarum Lesser galangal (ginger family) 21 19408-84-5
Dihydrocapsaicin Capsicum annuum Serrano pepper 22 30511-77-4
Isochavicine Piper longum, Long pepper, Piper nigrum Indian long
pepper; black pepper 23 517-73-7 Melicopicine Teclea trichocarpa 24
Zanthoxylum esquirolii 25 41303-25-7 O-Methylglycosolone
Zanthoxylum esquirolii 26 5307-59-5 Robustic acid Derris robusta 27
84-99-1 Xanthoxyletin Toddalia asiatica; Orange climber Millettia
pulchra 28 4335-12-0 Toddaculin Toddalia asiatica Orange climber 29
351427-18-4 Vitetrifolin D Vitex agnus Vitex, Chaste Tree,
Chasteberry, Abraham's Balm, Monk's Pepper 30 61263-52-3 Vitex
agnus Vitex, Chaste Tree, Chasteberry, Abraham's Balm, Monk's
Pepper 31 465-92-9 Marrubin Marrubium vulgare White Horehound,
Common Horehound 32 238088-78-3 Orthosiphol I Orthosiphon stamineus
Cat whiskers 33 345905-36-4 Orthosiphol M Orthosiphon stamineus Cat
whiskers 34 254896-53-2 Aesculioside A Aesculus hippocastaneum
Horse-chestnut, conker tree 35 Gleditschia australis Locust tree 36
1383715-41-0 Pithecoctenium echinatum Monkey comb 37 Yucca gloriosa
Spanish dagger 38 Nephelium cuspidatum Bayong 39 20874-52-6
Saikosaponin D Bupleurum falcatum Chinese throroughwax; Sickle
hare's ear 40 1217879-76-9 a 3-benzofurancarboxylic Salvia
miltiorrhiza Red sage, Chinese ester sage, tan shen, or danshen 41
27994-11-2 Cimigoside; Cimicifuga racemosa Black cohosh,
b-D-Xylopyranoside black bugbane, black snakeroot, fairy candle 42
4373-41-5 Maslinic acid, Alchemilla xanthochlora Lady's Mantle
Crategolic acid 43 77-52-1 Ursolic acid Lavandula officinalis
Lavender, English lavender, common lavender, true lavender,
narrow-leaved lavender 44 58546-54-6 Schizandrol B; Schisandra
chinensis Five flavor berry Gomisin A 45 61281-38-7 Schisandrin A,
Schisandra chinensis Five flavor berry Deoxyschizandrin 46
61281-37-6 Schizandrin B Schisandra chinensis Five flavor berry 47
102036-29-3 Protosappanin B 48 129102-89-2 Secoisolariciresinol;
Angelica archangelica Garden Angelica, Secoisolariciresin-4-yl Holy
Ghost, Wild b-D-glucopyranoside Celery, Norwegian angelica 49
66322-34-7 Dihydroguaiaretic acid Schisandra chinensis Five flavor
berry 50 193816-85-2 Epicalyxin C Alpinia katsumadai Greater
galangal 51 181490-70-0 Icariin Angelica sinensis dong quai or
female ginseng 52 446030-43-9 Myrrhanone B Commiphora mukul Guggul,
Indian Bdellium 53 936499-55-7 Brevifolin Zanthoxylum piperitum
Japanese pepper, Japanese pricklyash 54 1083202-45-2 Fungus Strain
code: 01469fxxx000005 55 Erythrina variegata Tiger's claw or Indian
coral tree 56 155485-76-0 Senecrassidiol Psidium guajava Apple
guava or common guava 57 84-26-4 Rutaecarpine Evodia rutaecarpa
Evodia fruit 58 992-20-1 Salannin Azadirachta indica Neem, Nimtree
and Indian Eilac 59 69222-20-4 Isoanthricin Podophyllum peltatum
May Apple, hogapple, Indian apple, mayflower, umbrella plant, wild
mandrake, American mandrake 60 850494-43-8 Mammea A/AD cyclo Mesua
ferrea Ceylon ironwood, F Indian rose chestnut, or Cobra's saffron
61 7282-19-1 Atanine Zanthoxylum piperitum Japanese pepper,
Japanese pricklyash 62 484-20-8 Bergapten Petroselinum stativum
Parsley 63 133164-11-1 Prangol Petroselinum stativum Parsley 64
482-44-0 Imperatorin Petroselinum stativum Parsley 65 2543-94-4
Phellopterin Petroselinum stativum Parsley 66 497226-80-9 terpenoid
coumarins Ferula assa-foetida Giant fennel, asant, food of the
gods, jowani badian, stinking gum, Devil's dung 67 484-33-3
Pongamol Millettia pulchra 68 artificial 69 1176891-50-1
Sakisacaulon A Lichen 70 1268481-32-8 Chalepin 71 1092383-76-0
Rutamarin 72 13164-03-9 Halepensin 73 143-62-4 Digitoxigenin
Xysmalobium undulatum Uzara 74 26241-51-0 Azadiradione Azadirachta
indica Neem, Nimtree, Indian Lilac 75 95975-55-6 (Z)-Guggulsterone
Commiphora mukul Guggul, Indian Bdellium 76 1941-73-7 Apobioside
Apocynum cannabinum Dogbane, Amy Root, Hemp Dogbane, Indian Hemp,
Rheumatism Root, Wild Cotton 77 3751-87-9 Apocannoside Apocynum
cannabinum Dogbane, Amy Root, Hemp Dogbane, Indian Hemp, Rheumatism
Root, Wild Cotton 78 86894-26-0 Hebelomic acid A Hebeloma senescens
mushroom methyl ester 79 2221-82-1 .beta.-Cyclocostunolide Critonia
morifolia 80a 546-43-0 Alantolactone Inula helenium Elecampane,
horse-heal, marchalan 80b 470-17-7 Isoalantolactone Inula helenium
Elecampane, horse-heal, marchalan 81 a
2-octenyl-3-hydroxy-1,5-pentanedioic Fungus Strain code acid
02295fxxx000001 82 83797-45-9 16-Heptadecene-1,2,4-triol; Persea
gratissima Avocado Avocadene 83 1356361-43-7
16-Heptadecene-1,2,4-triol, 1,4-diacetate Persea gratissima Avocado
84 16423-52-2 N-Decyl acetamide Bacteria Strain code 0172axxx000002
85 21402-68-6 9-hydroxy-10,12,15-Octadecatrienoic Marrubium vulgare
White Horehound, acid Common Horehound 86 167936-49-4
12-hydroxy-9,13,15-Octadecatrienoic Petroselinum stativum Parsley
acid 87 Ricinus communis Castor oil plant 88 15514-85-9
Dimorphecolic acid Podophyllum peltatum May Apple, hogapple, Indian
apple, mayflower, umbrella plant, wild mandrake, American mandrake
89 463-40-1 Linolenic acid Mesua ferrea Ceylon ironwood, Indian
rose chestnut, Cobra's saffron 90 35949-86-1 Gingerglycolipid C
Zingiber officinalis Ginger 91 187218-23-1 Capsianoside E Capsicum
annuum Serrano pepper 92 131580-15-9 Capsianoside D Capsicum annuum
Serrano pepper 93 22338-69-8 Grandifloric acid Aralia cordata,
Spikenard, udo Espeletia spp. 94 6619-97-2 Xylopic acid Xylopia
aethiopica Bitterwood 95 32381-03-6 Angeloylgrandifloric acid
Sideritis hirsuta Hairy ironwort 96 482-00-8 Lanceolatin B 97
101140-06-1 Biapigenin Fagopyrum esculentum, Hypericum perforatum
98 64125-32-2 Millettia pulchra 99 36640-12-7 Lichen
[0056] Compounds 12 and 20 are the same compound isolated from
different sources.
[0057] The CAS registry numbers presented in Table 1 above reflect
a compound or an isomer thereof. It will be understood that other
isomers may have other CAS registry numbers. Further, the
structures presented herein, to the extent that they show
stereochemistry may not match the particular isomer of the CAS
registry number presented in Table 1.
[0058] Those compounds for which no CAS registry numbers are
provided in Table 1, as well as those for which registry numbers
are provided, may be isolated or purified in any suitable manner.
For example, the natural source of the compound, which is presented
in Table 1, may be fractionated and the fractions subjected to
chromatography, such as gas chromatography or HPLC, or other
suitable separation process to isolate or purify the compound. The
selection of, for example, a chromatography column and parameters
can be readily identified based on the chemical structure of the
compound. To facilitate isolation or purification or for
verification, obtained fractions, subfractions, or individual
compounds may be tested for ability to activate a sodium channel,
for example, expressed in cells in culture, cell membrane, or the
like and employing an appropriate assay, such as an
electrophysiological assay, a colorimetric assay, or the like.
[0059] Alternatively or in addition, the compounds listed in Table
1 may be synthesized. Alternatively or in addition, companies that
have access to the appropriate natural sources or the ability to
test for sodium channel activity may be contracted to isolate the
compounds. Companies that have access to natural products or
natural product libraries that may include sources presented in
Table 1 or that have expertise in development of assays for
identification of compounds or fractions containing compounds
capable of activating a sodium channel include Biotechnology
Research And Information Network AG (Zwingengerg, Germany);
AnalytiCon Discovery, GmbH (Potsdam, Germany); Albany Molecular
Research, Inc. (Albany, N.Y., USA); Axxam SpA (Milan, Italy);
Boulder BioPharmaceuticals, LLC, Boulder, Colo.; ChromaDex (Irvine,
Calif., USA); Enzo Life Sciences, Inc. (Farmingdale, N.Y., USA);
IMD Natural Solutions GmbH (Dortmund, Germany); TimTec LLC (Newark,
Del., USA); and The Natural Products Discovery Institute
(Doylestown, Pa., USA).
[0060] The structures of the initially selected compounds are as
follows:
##STR00001## ##STR00002## ##STR00003## ##STR00004## ##STR00005##
##STR00006## ##STR00007## ##STR00008## ##STR00009## ##STR00010##
##STR00011##
[0061] Presented below are chemical compound structures based on
groupings of structural relationships of the 99 initially selected
compounds. The compounds are grouped into 21 categories (A through
U) containing one or more of the 99 initially selected compounds.
Within some categories, sub-categories are described.
[0062] In some instances, a compound may be in more than one
category due to its structural similarity to compounds in more than
one category. It will be understood that structural similarities of
the various compounds other than those presented herein exist and
that groupings into categories other than those presented herein
are possible and contemplated.
[0063] Each of the 22 categories of compounds presented herein is
discussed independently. That is, discussion of substituents with
regard to one category should not be construed to limit discussion
of substituents with regard to another category. For example,
R.sup.1 for the group A compounds is independently defined relative
to R.sup.1 for the group B compounds. In addition, discussion of
substituents with regard to subgroups is independently defined. For
example, R.sup.1 for the group J1 compounds is independently
defined relative to R.sup.1 for the group J2 compounds, unless
otherwise stated.
[0064] Group a Compounds
[0065] In embodiments, a bioactive, taste modulating, or salty
taste modulating compound is a compound having the following
structure:
##STR00012## [0066] where: [0067] R.sup.1 is H or C.sub.1-C.sub.10
alkyl; [0068] R.sup.2 is H or C.sub.1-C.sub.3 alkyl; [0069] X is
CHOR.sup.3 or C.dbd.O;
[0069] ##STR00013## [0070] R.sup.3 is H, C.sub.1-C.sub.3 alkyl, or
[0071] R.sup.4 is H or C.sub.1-C.sub.3 alkyl; [0072] Y is
CR.sup.5.dbd.CH or CHR.sup.5--CH.sub.2; [0073] R.sup.5 is H, OH,
--OCH.sub.3, --OCH.sub.2CH.sub.3, --O--OCH.sub.2CH.sub.2CH.sub.3,
or
[0073] ##STR00014## [0074] and [0075] R.sup.6 is H or
C.sub.1-C.sub.3 alkyl.
[0076] In embodiments, R.sup.1 is C.sub.2-C.sub.8 alkyl. In
embodiments, R.sup.2 is H. In embodiments, X is C.dbd.O or
##STR00015##
where R.sup.4 is CH.sub.3. In embodiments, when Y is
CR.sup.5.dbd.CH, R.sup.5 is H. In embodiments, when Y is
CHR.sup.5--CH.sub.2, R.sup.5 is OH or --OCH.sub.3. In embodiments,
R.sup.6 is CH.sub.3.
[0077] Group B Compounds
[0078] Group B1 Compounds
[0079] In embodiments, a bioactive, taste modulating, or salty
taste modulating compound is a compound having the following
structure:
##STR00016##
[0080] where: [0081] R.sup.1 and R.sup.2 are each independently OH
or C.sub.1-C.sub.3 alkoxy or where R.sup.1 and R.sup.2 together
with the carbons to which they are bound form a five-membered ring
having two oxygen heteroatoms to form a compound having the
following structure
##STR00017## ##STR00018##
[0082] Group B2 Compounds
[0083] In embodiments, a bioactive, taste modulating, or salty
taste modulating compound is a compound having the following
structure:
##STR00019##
[0084] where R.sup.1 is C.sub.10-C.sub.15 alkyl or alkenyl.
[0085] Group B3 Compounds
[0086] In embodiments, a bioactive, taste modulating, or salty
taste modulating compound is a compound having the following
structure:
##STR00020##
[0087] where: [0088] R.sup.1 and R.sup.2 are each independently OH
or C.sub.1-C.sub.3 alkoxy, and [0089] R.sup.3 is selected from the
group consisting of [0090] (i) C.sub.10-C.sub.20 unsubstituted
straight or branched chain alkenyl with one or more double bonds;
and [0091] (ii)
[0091] ##STR00021## [0092] where X, Y and Z are independently CH,
CH.sub.2, CO or CHOR.sup.5 where R.sup.5 is H or C.sub.1-C.sub.3
alkyl, provided that if one of X or Y are CH then Z is also CH, and
where R.sup.4 is C.sub.1-C.sub.8 straight or branched chain
unsubstituted alkyl or
[0092] ##STR00022## [0093] where n is 1-5, provided that if R.sup.4
is C.sub.1-C.sub.8 straight or branched chain alkyl, then Y is
CHOR.sup.5 where R.sup.5 is C.sub.1-C.sub.3 alkyl.
[0094] In embodiments, R.sup.1 and R.sup.2 are OH. In such
embodiments, R.sup.1 may be substituted at the 5 position, R.sup.2
may be substituted at the 3 position, and R.sup.3 may be
substituted at the 1 position.
[0095] In embodiments, R.sup.3 is C.sub.10-C.sub.20 unsubstituted
straight or branched chain alkenyl with one or more double bonds.
In such embodiments, R.sup.3 may be C.sub.12-C.sub.18 unsubstituted
straight or branched chain alkenyl. For example, R.sup.3 may be
C.sub.13-C.sub.17 unsubstituted straight or branched chain alkenyl,
such as C.sub.15 unsubstituted straight or branched chain alkenyl.
In embodiments, R.sup.3 has 1-5 double bonds. For example, R.sup.3
may have 1-4 double bonds, such as 1-3 double bonds. In
embodiments, R.sup.3 is a straight chain alkenyl. By way of
example, R.sup.3 may be
##STR00023##
[0096] In embodiments, R.sup.1 is C.sub.1-C.sub.3 alkoxy, such as
methoxy, and R.sup.2 is OH. In such embodiments, R.sup.1 may be
substituted at the 3 position, R.sup.2 may substituted at the 4
position, and R.sup.3 may substituted at the 1 position.
[0097] In embodiments, R.sup.3 is
##STR00024##
In such embodiments, R.sup.4 may be
##STR00025##
In embodiments, n is 2. In embodiments, Z is CH or CH.sub.2, X and
Z are each independently CH or CH.sub.2, depending on whether Z is
CH or CH.sub.2. In embodiments, X is CHOR.sup.5. R.sup.5 may be H.
In embodiments, Y is CO. In embodiments, X is CO. By way of
example, R.sup.3 may be
##STR00026##
[0098] In embodiments, Y is CHOR.sup.5. R.sup.5 may be
C.sub.1-C.sub.3 alkyl. For example, R.sup.5 may be methyl. In some
embodiments, where Y is CHOR.sup.5, R.sup.4 is C.sub.1-C.sub.8
straight or branched chain alkyl. For example, R.sup.4 may be
C.sub.4-C.sub.6 straight or branched chain alkyl, such as C.sub.5
straight or branched chain alkyl. IN embodiments, R.sup.4 is a
straight chain alkyl.
[0099] In embodiments, R.sup.3 is
##STR00027##
[0100] In embodiments, R.sup.3 is selected from the group
consisting of:
##STR00028##
[0101] Group B4 Compounds
[0102] In embodiments, a bioactive, taste modulating, or salty
taste modulating compound is a compound having the following
structure:
##STR00029## [0103] where: [0104] A and B are each independently
NCH.sub.3 or C(O), with the proviso that one of A and B is
NCH.sub.3 and the other of A and B is C(O); and [0105] R.sub.1 and
R.sub.2 are independently selected from H or C.sub.8-C.sub.16
unsaturated alkyl, with the proviso that if one of R.sub.1 and
R.sub.2 is H, then the other of R.sub.1 and R.sub.2 is
C.sub.8-C.sub.16 unsaturated alkyl.
[0106] In embodiments, R.sub.1 and R.sub.2 are independently
selected from H or C.sub.8-C.sub.16 unsaturated alkyl, wherein the
C.sub.8-C.sub.16 unsaturated alkyl contains 1 to 3 double bonds. In
embodiments, R.sub.1 and R.sub.2 are independently selected from H
or C.sub.8-C.sub.16 unsaturated alkyl, wherein the C.sub.8-C.sub.16
unsaturated alkyl contains only 1 double bond.
[0107] In embodiments, B is NCH.sub.3 and R.sub.2 is
C.sub.8-C.sub.16 unsaturated alkyl.
[0108] In embodiments, R.sub.1 and R.sub.2 are independently
selected from H or C.sub.11-C.sub.15 unsaturated alkyl, such as
C.sub.13 unsaturated alkyl.
[0109] Group C Compounds
[0110] In embodiments, a bioactive, taste modulating, or salty
taste modulating compound is a compound having the following
structure:
##STR00030##
[0111] where: [0112] X is C or N; [0113] R.sup.1 is H, OH,
C.sub.1-C.sub.3 alkoxy, or C.sub.1-C.sub.6 alkyl; [0114] R.sup.2
and R.sup.3 are each independently selected from H; OH;
C.sub.1-C.sub.3 alkoxy; straight or branched chain, saturated or
unsaturated C.sub.1-C.sub.6 alkyl or alkenyl; or R.sup.1 and
R.sup.2 together with the carbons to which they are bound form a
part of a five or six membered ring structure; [0115] R.sup.4 is H
or C.sub.1-C.sub.3 alkyl; [0116] R.sup.5 is H, OH, C.sub.1-C.sub.3
alkoxy or C.sub.1-C.sub.3 alkyl; [0117] A and B are each
independently selected from CH, C.dbd.O, C-benzyl methoxy,
C--CH.sub.2--R.sup.6 or C--C(O)R.sup.6 where R.sup.6 is straight or
branched chain, saturated or unsaturated C.sub.1-C.sub.6 alkyl, or
A and B together are part of an aromatic six-membered ring
structure sharing a side with the remainder of the structure of
Formula (C); and [0118] Y is O, CH, C.dbd.O, or C--O--R.sup.7,
where R.sup.7 is H or C.sub.1-C.sub.3 alkyl.
[0119] In embodiments, when X is N, R.sup.5 is C.sub.1-C.sub.3
alkyl, such as methyl. In embodiments, when X is N, Y is C.dbd.O or
C--O--R.sup.7, such as C--O-Me. In embodiments when X is C, R.sup.5
is H or OH. In embodiments when X is C, Y is O. In embodiments,
R.sup.1 is H or methoxy. In embodiments, one of A or B is C.dbd.O
and the other is H, C-benzyl methoxy,
C--CH.sub.2CHC(CH.sub.3).sub.2 or C--C(O)CHC(CH.sub.3).sub.2.
[0120] In embodiments, R.sup.2 and R.sup.3 together with the
carbons to which they are bound form a part of a six membered ring
structure. In embodiments, the six membered ring structure includes
an oxygen or nitrogen heteroatom. In embodiments, the six membered
ring structure contains one or more carbon atoms substituted with
one or more C.sub.1-C.sub.6 alkyl, such as methyl. In embodiments,
one carbon atom of the ring structure is substituted with two
methyl groups. In embodiments, the ring structure is an
unsubstituted six carbon aromatic ring structure.
[0121] In embodiments, a compound according to Formula (C) has the
following structure:
##STR00031##
where A, B, X, Y, R', R.sup.4 and R.sup.5 are as described above
for Formula (C).
[0122] In embodiments, a compound according to Formula (C) has the
following structure:
##STR00032## [0123] where: [0124] R.sup.1, R.sup.2 and R.sup.3 are
each independently H, OH or C.sub.1-C.sub.3 alkoxy; [0125] R.sup.4
and R.sup.5 are each independently H or C.sub.1-C.sub.3 alkyl;
[0126] Y is C.dbd.O or C--O--R.sup.7, where R.sup.7 is H or
C.sub.1-C.sub.3 alkyl; and [0127] A is C--CH.sub.2--R.sup.6 or
C--C(O)R.sup.6 where R.sup.6 is straight or branched chain,
saturated or partially unsaturated C.sub.1-C.sub.6 alkyl, B is
C.dbd.O, or A and B together are part of an aromatic six-carbon
membered ring structure sharing a side with the remainder of the
structure of Formula (C'').
[0128] In embodiments of a compound according to Formula (C''),
R.sup.1, R.sup.2 and R.sup.3 are H.
[0129] In embodiments, A is C--CH.sub.2--R.sup.6 or C--C(O)R.sup.6
where R.sup.6 is straight or branched chain, saturated or partially
unsaturated C.sub.1-C.sub.6 alkyl and B is C.dbd.O.
[0130] In embodiments, R.sup.1, R.sup.2 and R.sup.3 are each
independently OH or C.sub.1-C.sub.3 alkoxy. In some embodiments,
R.sup.1, R.sup.2 and R.sup.3 are the same.
[0131] In embodiments, A and B together are part of an aromatic
six-carbon membered unsubstituted ring structure.
[0132] In embodiments, a compound according to Formula (C) has the
following structure:
##STR00033## [0133] where: [0134] R.sup.1, R.sup.2 and R.sup.3 are
each independently H, OH or C.sub.1-C.sub.3 alkoxy; [0135] R.sup.4
and R.sup.5 are each independently H or C.sub.1-C.sub.3 alkyl;
[0136] Y is C.dbd.O or C--O--R.sup.7, where R.sup.7 is H or
C.sub.1-C.sub.3 alkyl; and [0137] A is C--CH.sub.2--R.sup.6 or
C--C(O)R.sup.6 where R.sup.6 is straight or branched chain,
saturated or partially unsaturated C.sub.1-C.sub.6 alkyl, B is
C.dbd.O, or A and B together are part of an aromatic six-carbon
membered ring structure sharing a side with the remainder of the
structure of Formula (C'').
[0138] In embodiments of a compound according to Formula (C'''),
R.sup.1, R.sup.2 and R.sup.3 are H. In embodiments, A is
C--CH.sub.2--R.sup.6 or C--C(O)R.sup.6 where R.sup.6 is straight or
branched chain, saturated or partially unsaturated C.sub.1-C.sub.6
alkyl and B is C.dbd.O. In embodiments, R.sup.1, R.sup.2 and
R.sup.3 are each independently OH or C.sub.1-C.sub.3 alkoxy. In
embodiments, R.sup.1, R.sup.2 and R.sup.3 are the same. In
embodiments, A and B together are part of an aromatic six-carbon
membered unsubstituted ring structure.
[0139] In embodiments, a compound according to Formula (C) has the
following structure:
##STR00034## [0140] where: [0141] X is N; [0142] R.sup.1 is H or
C.sub.1-C.sub.3 alkyl; [0143] R.sup.2 and R.sup.3 are each
independently selected from H and straight or branched chain,
saturated or unsaturated C.sub.1-C.sub.3 alkyl or alkenyl; [0144]
R.sup.4 is H or C.sub.1-C.sub.3 alkyl; [0145] R.sup.5 is H or
C.sub.1-C.sub.3 alkyl; [0146] A and B are each independently
selected from C.dbd.O and C--C(O)R.sup.6 where R.sup.6 is straight
or branched chain, saturated or partially unsaturated
C.sub.1-C.sub.6 alkyl; and [0147] Y is C--O--R.sup.7, where R.sup.7
is H or C.sub.1-C.sub.3 alkyl.
[0148] In embodiments of a compound according to Formula (C''''),
one or more of R.sup.1, R.sup.2 and R.sup.3 are H. In embodiments,
each of R.sup.1, R.sup.2 and R.sup.3 are H. In embodiments, R.sup.4
and R.sup.5 are independently C.sub.1-C.sub.3 alkyl. In
embodiments, R.sup.4 and R.sup.5 are methyl. In embodiments,
wherein A is C--C(O)R.sup.6. In embodiments, B is C.dbd.O.
[0149] Group D Compounds
[0150] In embodiments, a bioactive, taste modulating, or salty
taste modulating compound is a compound having the following
structure:
##STR00035## [0151] where: [0152] R.sup.1 is H, methyl, OCOCH.sub.3
or forms together with R.sup.6 a five membered ring structure in
which R.sup.1 and R.sup.6 together are C.dbd.O or CH.sub.2; [0153]
R.sup.6 is H, C.dbd.OCH.sub.3, or together forms a five membered
ring structure in which R.sup.1 and R.sup.6 together are C.dbd.O or
CH.sub.2; [0154] R.sup.7 is OCOCH.sub.3; [0155] A and B are C, CH
or CCH.sub.3, wherein when A and B are both C a double bond is
formed between A and B; and [0156] R.sup.4 and R.sup.5 are
independently selected from OH, methyl,
[0156] ##STR00036## [0157] or [0158] R.sup.4 and R.sup.5 together
with the carbon to which they are bound form
[0158] ##STR00037## [0159] to form a compound of the following
formula
[0159] ##STR00038## [0160] where R.sup.1, R.sup.6 and R.sup.7 are
as described above.
[0161] Group E Compounds
[0162] In embodiments, a bioactive, taste modulating, or salty
taste modulating compound is a compound having the following
structure:
##STR00039##
[0163] where R.sup.1, R.sup.2 and R.sup.3 are independently
selected from the group consisting of H and COCH.sub.3.
[0164] Group F Compounds
[0165] In embodiments, a bioactive, taste modulating, or salty
taste modulating compound is a compound having the following
structure:
##STR00040## [0166] where: [0167] R.sup.42 is H or OH; [0168]
R.sup.43 are R.sup.44 each independently H or CH.sub.3; [0169]
R.sup.1 and R.sup.2 are each independently OH, C.sub.1-C.sub.3
alkyl or C.sub.1-C.sub.3 hydroxyl; [0170] R.sup.3 and R.sup.4 are
each independently H, OH or C.sub.1-C.sub.3 hydroxyl; [0171]
R.sup.5 is H or --OC(O)R.sup.8, where R.sup.8 is C.sub.1-C.sub.8
straight or branched chain, saturated or unsaturated alkyl; [0172]
W is CH; [0173] Y is CH, X is CH or CH.sub.2, and Z is C or
CR.sup.9, provided that Z is C when X is CH.sub.2, where R.sup.9 is
H or together with R.sup.6 and the carbons to which they are bound
and the intervening carbon of W form a five membered ring with an
oxygen heteroatom; [0174] R.sup.6 is C.sub.1-C.sub.3 hydroxyl,
C(O)R.sup.10, (CH.sub.2)p'R.sup.10 where p' is zero or 1, or
together with R.sup.9 and the carbons to which they are bound and
the intervening carbon of W form a five membered ring with an
oxygen heteroatom, [0175] where R.sup.10 is H, OH, or saccharidyl;
and [0176] R.sup.7 is H, OH, C.sub.1-C.sub.3 hydroxyl, or
(CH.sub.2).sub.pR.sup.44, where p is zero or 1 and R.sup.44 is
saccharidyl.
[0177] In embodiments, R.sup.10 is saccharidyl and is
##STR00041## [0178] where a and b are each independently zero or 1;
[0179] where R.sup.11 is H or
[0179] ##STR00042## [0180] where d is zero or 1, [0181] R.sup.14 is
H, OH, CH.sub.3 or C.sub.1-C.sub.3 hydroxyl, and [0182] R.sup.15 is
H, C(O)R.sup.16 where R.sup.16 is C.sub.1-C.sub.15 straight or
branched chain, saturated or unsaturated alkyl unsubstituted or
substituted with hydroxyl, [0183] where R.sup.12 and R.sup.13 are
each independently H, C(O)R.sup.41 where R.sup.41 is
C.sub.1-C.sub.15 straight or branched chain, saturated or
unsaturated alkyl unsubstituted or substituted with hydroxyl,
or
[0183] ##STR00043## [0184] where e is zero or 1, [0185] R.sup.17 is
H, OH or CH.sub.3, and [0186] R.sup.18 is H, C(O)R.sup.42 where
R.sup.42 is C.sub.1-C.sub.15 straight or branched chain, saturated
or unsaturated alkyl unsubstituted or substituted with hydroxyl,
or
[0186] ##STR00044## [0187] where f is zero or 1, [0188] R.sup.19 is
H, OH or CH.sub.3, and [0189] R.sup.20 and R.sup.21 are each
independently H, C(O)R.sup.43 where R.sup.43 is C.sub.1-C.sub.15
straight or branched chain, saturated or unsaturated alkyl
unsubstituted or substituted with hydroxyl, or
[0189] ##STR00045## [0190] where [0191] g is zero or 1, and [0192]
R.sup.22, R.sup.23 and R.sup.24 are each independently H, OH or
CH.sub.3.
[0193] In embodiments, R.sup.44 is saccharidyl and is
##STR00046## [0194] where [0195] i is zero or 1, [0196] R.sub.25,
R.sub.26, R.sup.27 and R.sup.28 are each independently H, OH,
CH.sub.3, C.sub.1-C.sub.3 hydroxyl, COOH, (CH.sub.2)--OC(O)R.sup.29
where n is zero, 1, 2 or 3 and R.sup.29 is H or C.sub.1-C.sub.3
alkyl, or (CH.sub.2).sub.mOR.sup.30 where m is zero or 1 and
R.sup.30 is
[0196] ##STR00047## [0197] where [0198] j is zero or 1, [0199]
R.sup.31, R.sup.32, R.sup.33 and R.sup.34 are each independently H,
OH, CH.sub.3, C.sub.1-C.sub.3 hydroxyl, COOH,
(CH.sub.2).sub.qOC(O)R.sup.35 where q is zero, 1, 2 or 3 and
R.sup.35 is H or C.sub.1-C.sub.3 alkyl, or
(CH.sub.2).sub.tOR.sup.36 where t is zero or 1 and R.sup.36 is
[0199] ##STR00048## [0200] where [0201] k is zero or 1, and [0202]
R.sup.37, R.sup.38, R.sup.39 and R.sup.40 are each independently H,
OH, CH.sub.3, C.sub.1-C.sub.3 hydroxyl, COOH,
(CH.sub.2).sub.uOC(O)R.sup.41 where u is zero, 1, 2 or 3 and
R.sup.41 is H or C.sub.1-C.sub.3 alkyl.
[0203] In embodiments, Z is C. In embodiments, Z is CR.sup.9 and
wherein R.sup.9 together with R.sup.6 and the carbons to which they
are bound and the intervening carbon of W for a five membered ring
with an oxygen heteroatom. In embodiments, R.sup.6 is C(O)R.sup.10.
In embodiments, R.sup.10 is H or OH. In embodiments, R.sup.7 is OH.
In embodiments, R.sup.1 and R.sup.2 are each independently
C.sub.1-C.sub.3 alkly or C.sub.1-C.sub.3 hydroxyl. In embodiments,
R.sup.3 is H or OH. In embodiments, R.sup.4 is H. In embodiments,
R.sup.5 is H. In embodiments, one or more of R.sup.16, if present,
R.sup.42 and R.sup.43 are
##STR00049##
[0204] In embodiments, a compound according to Formula (F) has the
following structure:
##STR00050##
[0205] where: [0206] R.sup.1 and R.sup.2 are each independently OH,
C.sub.1-C.sub.3 alkyl or C.sub.1-C.sub.3 hydroxyl; [0207] R.sup.3
and R.sup.4 are each independently H, OH or C.sub.1-C.sub.3
hydroxyl; [0208] R.sup.5 is H; [0209] W is CH; [0210] Y is CH, X is
CH or CH.sub.2, and Z is C or CR.sup.9, provided that Z is C when X
is CH.sub.2, where R.sup.9 is H or together with R.sup.6 and the
carbons to which they are bound and the intervening carbon of W
form a five membered ring with an oxygen heteroatom; [0211] R.sup.6
is C.sub.1-C.sub.3 hydroxyl, C(O)R.sup.10, (CH.sub.2)p'R.sup.10
where p' is zero or 1, or together with R.sup.9 and the carbons to
which they are bound and the intervening carbon of W form a five
membered ring with an oxygen heteroatom, [0212] where R.sup.10 is H
or saccharidyl; and [0213] R.sup.7 is H, OH, C.sub.1-C.sub.3
hydroxyl, or (CH.sub.2).sub.pOR.sup.44, where p is zero or 1 and
R.sup.44 is saccharidyl.
[0214] In embodiments of a compound according to Formula F',
R.sup.10 is saccharidyl and is
##STR00051## [0215] where a and b are each independently zero or 1;
[0216] R.sup.11 is H or
[0216] ##STR00052## [0217] where d is zero or 1, [0218] R.sup.14 is
H, OH, CH.sub.3 or C.sub.1-C.sub.3 hydroxyl, and [0219] R.sup.15 is
H, C(O)R.sup.16 where R.sup.16 is C.sub.1-C.sub.15 straight or
branched chain, saturated or unsaturated alkyl unsubstituted or
substituted with hydroxyl, [0220] where R.sup.12 and R.sup.13 are
each independently H, C(O)R.sup.41 where R.sup.41 is
C.sub.1-C.sub.15 straight or branched chain, saturated or
unsaturated alkyl unsubstituted or substituted with hydroxyl,
or
[0220] ##STR00053## [0221] where e is zero or 1, [0222] R.sup.17 is
H, OH or CH.sub.3 and [0223] R.sup.18 is H, C(O)R.sup.42 where
R.sup.42 is C.sub.1-C.sub.15 straight or branched chain, saturated
or unsaturated alkyl unsubstituted or substituted with hydroxyl,
or
[0223] ##STR00054## [0224] where f is zero or 1, [0225] R.sup.19 is
H, OH or CH.sub.3, and [0226] R.sup.20 and R.sup.21 are each
independently H, C(O)R.sup.43 where R.sup.43 is C.sub.1-C.sub.15
straight or branched chain, saturated or unsaturated alkyl
unsubstituted or substituted with hydroxyl, or
[0226] ##STR00055## [0227] where [0228] g is zero or 1, and [0229]
R.sup.22, R.sup.23 and R.sup.24 are each independently H, OH or
CH.sub.3.
[0230] In embodiments of a compound according to Formula F',
R.sup.44 is saccharidyl and is
##STR00056## [0231] where [0232] i is zero or 1, and [0233]
R.sup.25, R.sup.26, R.sup.27 and R.sup.28 are each independently H,
OH, CH.sub.3, C.sub.1-C.sub.3 hydroxyl, COOH,
(CH.sub.2)--OC(O)R.sup.29 where n is zero, 1, 2 or 3 and R.sup.29
is H or C.sub.1-C.sub.3 alkyl, or (CH.sub.2).sub.mOR.sup.30 where m
is zero or 1 and R.sup.30 is
[0233] ##STR00057## [0234] where [0235] j is zero or 1, and [0236]
R.sup.31, R.sup.32, R.sup.33 and R.sup.34 are each independently H,
OH, CH.sub.3, C.sub.1-C.sub.3 hydroxyl, COOH,
(CH.sub.2).sub.qOC(O)R.sup.35 where q is zero, 1, 2 or 3 and
R.sup.35 is H or C.sub.1-C.sub.3 alkyl, or
(CH.sub.2).sub.tOR.sup.36 where t is zero or 1 and R.sup.36 is
[0236] ##STR00058## [0237] where [0238] k is zero or 1, and [0239]
R.sup.37, R.sup.38, R.sup.39 and R.sup.40 are each independently H,
OH, CH.sub.3, C.sub.1-C.sub.3 hydroxyl, COOH,
(CH.sub.2).sub.uOC(O)R.sup.41 where u is zero, 1, 2 or 3 and
R.sup.41 is H or C.sub.1-C.sub.3 alkyl.
[0240] In embodiments of a compound according to Formula F', Z is
C. In embodiments, Z is CR.sup.9 and wherein R.sup.9 together with
R.sup.6 and the carbons to which they are bound and the intervening
carbon of W for a five membered ring with an oxygen heteroatom. In
embodiments, R.sup.6 is C(O)R.sup.10. In embodiments, R.sup.1 and
R.sup.2 are each independently C.sub.1-C.sub.3 alkly or
C.sub.1-C.sub.3 hydroxyl. In embodiments, R.sup.3 is H or OH. In
embodiments, R.sup.4 is H. In embodiments, R.sup.16, if present,
is
##STR00059##
[0241] In embodiments, a compound according to Formula (F) has the
following structure:
##STR00060## [0242] where: [0243] R.sup.1 and R.sup.2 are each
independently OH, C.sub.1-C.sub.3 alkyl or C.sub.1-C.sub.3
hydroxyl; [0244] R.sup.3 is H; [0245] R.sup.4 is H, OH or
C.sub.1-C.sub.3 hydroxyl; [0246] R.sup.5 is H; [0247] W is CH;
[0248] Y is CH, X is CH or CH.sub.2, and Z is C or CR.sup.9,
provided that Z is C when X is CH.sub.2, where R.sup.9 is H or
together with R.sup.6 and the carbons to which they are bound and
the intervening carbon of W form a five membered ring with an
oxygen heteroatom; [0249] R.sup.6 is, together with R.sup.9 and the
carbons to which they are bound and the intervening carbon of W
form a five membered ring with an oxygen heteroatom, or
C(O)R.sup.10 [0250] where R.sup.10 is H or
[0250] ##STR00061## [0251] where a and b are each independently
zero or 1; [0252] where R.sup.11 is H, OH, or
[0252] ##STR00062## [0253] where d is zero or 1, [0254] R.sup.14 is
H, OH, CH.sub.3 or C.sub.1-C.sub.3 hydroxyl, and [0255] R.sup.15 is
H, C(O)R.sup.16 where R.sup.16 is C.sub.1-C.sub.15 straight or
branched chain, saturated or unsaturated alkyl unsubstituted or
substituted with hydroxyl, [0256] where R.sup.12 and R.sup.13 are
each independently H, C(O)R.sup.41 where R.sup.41 is
C.sub.1-C.sub.15 straight or branched chain, saturated or
unsaturated alkyl unsubstituted or substituted with hydroxyl,
or
[0256] ##STR00063## [0257] where e is zero or 1, [0258] R.sup.17 is
H, OH or CH.sub.3 and [0259] R.sup.18 is H, C(O)R.sup.42 where
R.sup.42 is C.sub.1-C.sub.15 straight or branched chain, saturated
or unsaturated alkyl unsubstituted or substituted with hydroxyl,
or
[0259] ##STR00064## [0260] where f is zero or 1, [0261] R.sup.19 is
H, OH or CH.sub.3, and [0262] R.sup.20 and R.sup.21 are each
independently H, C(O)R.sup.43 where R.sup.43 is C.sub.1-C.sub.15
straight or branched chain, saturated or unsaturated alkyl
unsubstituted or substituted with hydroxyl, or
[0262] ##STR00065## where g is zero or 1, and R.sub.22, R.sub.23
and R.sup.24 are each independently H, OH or CH.sub.3; and [0263]
R.sup.7 is H, OH, C.sub.1-C.sub.3 hydroxyl, or
(CH.sub.2).sub.pR.sup.44, where p is zero or 1 and R.sup.44 is
[0263] ##STR00066## [0264] where [0265] i is zero or 1, and [0266]
R.sup.25, R.sup.26, R.sup.27 and R.sup.28 are each independently H,
OH, CH.sub.3, C.sub.1-C.sub.3 hydroxyl, COOH,
(CH.sub.2)--OC(O)R.sup.29 where n is zero, 1, 2 or 3 and R.sup.29
is H or C.sub.1-C.sub.3 alkyl, or (CH.sub.2).sub.mOR.sup.30 where m
is zero or 1 and R.sup.30 is
[0266] ##STR00067## [0267] where [0268] j is zero or 1, and [0269]
R.sup.31, R.sup.32, R.sup.33 and R.sup.34 are each independently H,
OH, CH.sub.3, C.sub.1-C.sub.3 hydroxyl, COOH,
(CH.sub.2).sub.qOC(O)R.sup.35 where q is zero, 1, 2 or 3 and
R.sup.35 is H or C.sub.1-C.sub.3 alkyl, or
(CH.sub.2).sub.tOR.sup.36 where t is zero or 1 and R.sup.36 is
[0269] ##STR00068## [0270] where [0271] k is zero or 1, and [0272]
R.sup.37, R.sup.38, R.sup.39 and R.sup.40 are each independently H,
OH, CH.sub.3, C.sub.1-C.sub.3 hydroxyl, COOH,
(CH.sub.2)--OC(O)R.sup.41 where u is zero, 1, 2 or 3 and R.sup.41
is H or C.sub.1-C.sub.3 alkyl.
[0273] In embodiments of a compound according to Formula (F''),
R.sup.4 is H. In embodiments, R.sup.1 is CH.sub.3. In embodiments,
R.sup.2 is CH.sub.3.
[0274] Group G Compound
[0275] In embodiments, a bioactive, taste modulating, or salty
taste modulating compound is a compound having the following
structure:
##STR00069##
[0276] Group H Compounds
[0277] In embodiments, a bioactive, taste modulating, or salty
taste modulating compound is a compound having the following
structure:
##STR00070##
[0278] where: [0279] R.sup.1 is H or saccharidyl; [0280] R.sup.2 is
H or OH; [0281] R.sup.3 and R.sup.4 are independently selected from
H or methyl or together form CH.sub.2; [0282] R.sup.5 is CH.sub.2
or CH; [0283] R.sup.6 is CH or C, provided that when R.sup.5 is CH,
R.sup.6 is C; [0284] R.sup.7 and R.sup.8 together with the carbons
to which they are bound form
[0284] ##STR00071## [0285] to form a compound having the following
structure
[0285] ##STR00072## [0286] and [0287] R.sup.9, R.sup.10, and
R.sup.11 are independently H or methyl.
[0288] In embodiments, R.sup.1 is saccharidyl and is
##STR00073##
[0289] Group I Compounds
[0290] In embodiments, a bioactive, taste modulating, or salty
taste modulating compound is a compound having the following
structure:
##STR00074## [0291] where: [0292] X is O or CH.sub.2; [0293]
R.sup.1 and R.sup.9 are independently selected from H, OH,
C.sub.1-C.sub.3 alkoxy, C.sub.1-C.sub.3 alkyl, and (CH.sub.2)--OH,
where n is an integer from 1 to 3; [0294] R.sup.2 and R.sup.10 are
independently selected from H, OH and C.sub.1-C.sub.3 alkyl; [0295]
R.sup.3 and R.sup.4 are independently selected from H and
C.sub.1-C.sub.3 alkyl or together form CH.sub.2; [0296] R.sup.5,
R.sup.6 and R.sup.7 are independently selected from H and
C.sub.1-C.sub.3 alkyoxy; and [0297] R.sup.8 is H, OH or
C.sub.1-C.sub.3 alkyoxy.
[0298] In embodiments, R.sup.5, R.sup.6, R.sup.7 and R.sup.8 are
independently C.sub.1-C.sub.3 alkyoxy. In embodiments, R.sup.5,
R.sup.6, R.sup.7 and R.sup.8 are methoxy. In embodiments, R.sup.3
and R.sup.4 together form CH.sub.2. In embodiments, R.sup.3 and
R.sup.4 are independently C.sub.1-C.sub.3 alkyl. In embodiments,
R.sup.3 and R.sup.4 are methyl. In embodiments, at least two of
R.sup.1, R.sup.2, R.sup.9 and R.sup.10 are independently
C.sub.1-C.sub.3 alkyl. In embodiments, at least two of R.sup.1,
R.sup.2, R.sup.9 and R.sup.10 are methyl. In embodiments, X is
CH.sub.2.
[0299] In embodiments, X is O. In some embodiments where X is O,
R.sup.2 and R.sup.10 are H. In some embodiments where X is O, two
or more or R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7,
and R.sup.10 are H. In some embodiments where X is O, each of
R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, and R.sup.10
are H. In some embodiments where X is O, R.sup.8 is OH or
C.sub.1-C.sub.3 alkoxy. In some embodiments where X is O, R.sup.1
and R.sup.9 are independently selected from OH, C.sub.1-C.sub.3
alkoxy, and (CH.sub.2).sub.n--OH. In some embodiments where X is O,
one of R.sup.1 and R.sup.9 is selected from OH and C.sub.1-C.sub.3
alkoxy, and the other of R.sup.1 and R.sup.9 is
(CH.sub.2).sub.n--OH.
[0300] In embodiments, a compound according to Formula (I) has the
following structure:
##STR00075## [0301] where: [0302] X is O; [0303] R.sup.1 and
R.sup.9 are independently selected from H, OH, C.sub.1-C.sub.3
alkoxy, C.sub.1-C.sub.3 alkyl, and [0304] (CH.sub.2)--OH, where n
is an integer from 1 to 3; [0305] R.sup.2 and R.sup.10 are
independently selected from H, OH and C.sub.1-C.sub.3 alkyl; [0306]
R.sup.3 and R.sup.4 are independently selected from H and
C.sub.1-C.sub.3 alkyl; [0307] R.sup.5, R.sup.6 and R.sup.7 are H;
and [0308] R.sup.8 is H, OH or C.sub.1-C.sub.3 alkyoxy.
[0309] In embodiments of a compound according to Formula (I'),
R.sup.2 and R.sup.10 are H. In embodiments, each of R.sup.2,
R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, and R.sup.10 are H. In
embodiments, R.sup.8 is OH or C.sub.1-C.sub.3 alkoxy. In
embodiments, R.sup.1 and R.sup.9 are independently selected from
OH, C.sub.1-C.sub.3 alkoxy, and (CH.sub.2)--OH. In embodiments, one
of R.sup.1 and R.sup.9 is selected from OH and C.sub.1-C.sub.3
alkoxy, and the other of R.sup.1 and R.sup.9 is
(CH.sub.2).sub.n--OH.
[0310] Group J Compounds
[0311] Group J1 Compounds
[0312] In embodiments, a bioactive, taste modulating, or salty
taste modulating is a compound having the following structure:
##STR00076##
[0313] where: [0314] R.sup.1 and R.sup.6 are each independently OH,
C.sub.1-C.sub.3 hydroxyl, C.sub.1-C.sub.3 alkoxy or saccharidyl;
[0315] R.sup.2, R.sup.3, R.sup.7 and R.sup.8 are each independently
H, OH, C.sub.1-C.sub.3 hydroxyl, C.sub.1-C.sub.3 alkoxy; [0316]
R.sup.4 and R.sup.5 are each independently H, OH, C.sub.1-C.sub.3
alkyl, C.sub.1-C.sub.3 alkoxy, or C.sub.1-C.sub.3 hydroxyl; [0317]
Y is CHCH and n is zero or 1; and [0318] X is CHR.sup.9 and m is
zero or 1, where R.sup.9 is
[0318] ##STR00077## [0319] where R.sup.10, R.sup.11 and R.sup.12
are each independently OH, C.sub.1-C.sub.3 alkoxy, or
C.sub.1-C.sub.3 hydroxyl, [0320] provided that if n is 1, then m is
1.
[0321] In embodiments of a compound according to Formula J1,
R.sup.1, R.sup.6, or R.sup.1 and R.sup.6 are saccharidyl and
are
##STR00078##
[0322] In embodiments of a compound according to Formula J1,
R.sup.1 is OH. In embodiments, R.sup.2, R.sup.3, R.sup.7 and
R.sup.8 are each independently H or C.sub.1-C.sub.3 alkoxy. In
embodiments, where one of wherein R.sup.2 and R.sup.3 is H and the
other is C.sub.1-C.sub.3 alkoxy, one of R.sup.7 and R.sup.8 is H
and the other is C.sub.1-C.sub.3 alkoxy. In embodiments, R.sup.2,
R.sup.3, R.sup.7 and R.sup.8 are each H. In embodiments, R.sup.10
is present and is OH. In embodiments, R.sup.11 is present and is
C.sub.1-C.sub.3 alkoxy. In embodiments, R.sup.12 is present and is
OH. In embodiments, R.sup.9 is present and is
##STR00079##
where R.sup.10, R.sup.11, and R.sup.12 are as defined above.
[0323] In embodiments of a compound according to Formula J1, the
compound has the following structure:
##STR00080## [0324] where R.sup.1, R.sup.2, R.sup.3, R.sup.4,
R.sup.5, R.sup.6, R.sup.7, R.sup.8, and R.sup.9 are as defined
above.
[0325] In embodiments of a compound according to Formula J1, the
compound has the following structure:
##STR00081## [0326] where R.sup.1, R.sup.2, R.sup.3, R.sup.4,
R.sup.5, R.sup.6, R.sup.7, and R.sup.8 are as defined above.
[0327] In embodiments of a compound according to Formula J1, the
compound has the following structure:
##STR00082## [0328] where:
[0329] R.sup.1 and R.sup.6 are each independently OH,
C.sub.1-C.sub.3 hydroxyl, C.sub.1-C.sub.3 alkoxy or saccharidyl;
[0330] R.sup.2, R.sup.3, R.sup.7 and R.sup.8 are each independently
H, OH, C.sub.1-C.sub.3 hydroxyl, C.sub.1-C.sub.3 alkoxy; [0331]
R.sup.4 and R.sup.5 are each independently H, OH, C.sub.1-C.sub.3
alkoxy, or C.sub.1-C.sub.3 hydroxyl; [0332] Y is CHCH and n is zero
or 1; and [0333] X is CHR.sup.9 and m is zero or 1, where R.sup.9
is
[0333] ##STR00083## [0334] where R.sup.10, R.sup.11 and R.sup.12
are each independently OH, C.sub.1-C.sub.3 alkoxy, or
C.sub.1-C.sub.3 hydroxyl, [0335] provided that if n is 1, then m is
1.
[0336] In embodiments, R.sup.1, R.sup.6 or R.sup.1 and R.sup.6 are
saccharidyl and are
##STR00084##
In embodiments, R.sup.1 is OH. In embodiments, R.sup.2, R.sup.3,
R.sup.7 and R.sup.8 are each independently H or C.sub.1-C.sub.3
alkoxy. In embodiments, R.sup.2 and R.sup.3 is H and the other is
C.sub.1-C.sub.3 alkoxy, and one of R.sup.7 and R.sup.8 is H and the
other is C.sub.1-C.sub.3 alkoxy. In embodiments, R.sup.2, R.sup.3,
R.sup.7 and R.sup.8 are each H. In embodiments, R.sup.10 is present
and is OH. In embodiments, R.sup.11 is present and is
C.sub.1-C.sub.3 alkoxy. In embodiments, R.sup.12 is present and is
OH. In embodiments, R.sup.9 is present and is
##STR00085## [0337] where R.sup.10, R.sup.11, and R.sup.12 are as
defined above.
[0338] Group J2 Compounds
[0339] In embodiments, a bioactive, taste modulating, or salty
taste modulating compound is a compound having the following
structure:
##STR00086##
[0340] where [0341] R.sup.1 is H, OH, or saccharidyl; [0342]
R.sup.2 and R.sup.3 are each independently H or C.sub.1-C.sub.3
alkyl; [0343] R.sup.4 and R.sup.5 are each independently H,
[0343] ##STR00087## [0344] or CHC(R.sup.10)R.sup.11, where [0345]
R.sup.10 and R.sup.11 are each independently H or C.sub.1-5 alkyl
unsubstituted or substituted with one or more of OH and
[0345] ##STR00088## [0346] X is C.dbd.O or O; [0347] Y is C.dbd.O
or O, provided that when X is O, Y is C.dbd.O, or when X is
C.dbd.O, Y is O; [0348] A is CHR.sup.12 or CR.sup.12, where [0349]
R.sup.12 is H, OH, or saccharidyl; [0350] B is C or CH, provided
that if B is C then A is CR.sup.12.
[0351] In embodiments of a compound according to Formula J2,
R.sup.1 is saccharidyl and is
##STR00089## [0352] where [0353] a is zero or 1, and
[0354] R.sup.6, R.sup.7, R.sup.8, and R.sup.9 are each
independently H, OH, CH.sub.3, or CH.sub.2OH.
[0355] In embodiments of a compound according to Formula J2,
R.sup.12 is saccharidyl and is
##STR00090## [0356] where [0357] b is zero or 1, and [0358]
R.sup.13, R.sup.14, R.sup.15, and R.sup.16 are each independently
H, OH, CH.sub.3, or CH.sub.2OH.
[0359] In embodiments of a compound according to Formula J2,
R.sup.4 is CHC(CH.sub.3).sub.2 or
##STR00091##
[0360] In embodiments of a compound according to Formula J2,
R.sup.5 is H or
##STR00092##
[0361] Group K Compound
[0362] In embodiments, a bioactive, taste modulating, or salty
taste modulating compound is a compound having the following
structure:
##STR00093##
[0363] Group L Compounds
[0364] In embodiments, a bioactive, taste modulating, or salty
taste modulating compound is a compound having the following
structure:
##STR00094##
[0365] where: [0366] R.sup.1, R.sup.3, R.sup.4, R.sup.5 and R.sup.6
are each independently H, OH, C.sub.1-C.sub.3 hydroxyl or
C.sub.1-C.sub.3 alkoxy; and [0367] R.sup.2 is H, C.sub.1-C.sub.3
alkyl, or
[0367] ##STR00095## [0368] where R.sup.7, R.sup.8 and R.sup.9 are
each independently OH, C.sub.1-C.sub.3 hydroxyl or C.sub.1-C.sub.3
alkoxy.
[0369] In embodiments, R.sup.2 is C.sub.1-C.sub.3 alkyl, such as
methyl. In embodiments, R.sup.5 is OH or C.sub.1-C.sub.3 hydroxyl.
In embodiments, R.sup.3 is H. In embodiments, R.sup.4 is
C.sub.1-C.sub.3 alkoxy, such as methoxy. In embodiments, R.sup.6 is
C.sub.1-C.sub.3 alkyl, such as methyl or propyl. In embodiments,
R.sup.1 is H. In embodiments, R.sup.1 is C.sub.1-C.sub.3 hydroxyl,
such as C.sub.2 hydroxyl. In embodiments, R.sup.2 is
##STR00096##
In embodiments, R.sup.7, R.sup.8 and R.sup.9 are each independently
OH or C.sub.1-C.sub.3 alkoxy. In embodiments, R.sup.7 is OH and
R.sup.8 and R.sup.9 are each independently C.sub.1-C.sub.3 alkoxy,
such as methoxy.
[0370] In embodiments, R.sup.3 is OH, C.sub.1-C.sub.3 hydroxyl, or
C.sub.1-C.sub.3 alkoxy.
[0371] In embodiments, R.sup.5 is H.
[0372] In embodiments, R.sup.6 is C.sub.1-C.sub.3 alkoxy, such as
methoxy.
[0373] In embodiments, R.sup.1 is C.sub.1-C.sub.3 alkoxy, such as
methoxy.
[0374] In embodiments, R.sup.4 is H.
[0375] In embodiments of a compound according to Formula L, (i)
R.sup.1 is OH, C.sub.1-C.sub.3 hydroxyl or C.sub.1-C.sub.3 alkoxy;
(ii) R.sup.2 is H, C.sub.1-C.sub.3 alkyl, or
##STR00097##
where R.sup.7, R.sup.8 and R.sup.9 are each independently OH,
C.sub.1-C.sub.3 hydroxyl or C.sub.1-C.sub.3 alkoxy; and (iii)
R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are each independently H, OH,
C.sub.1-C.sub.3 hydroxyl or C.sub.1-C.sub.3 alkoxy. In embodiments,
R.sup.2 is C.sub.1-C.sub.3 alkyl, such as methyl. In embodiments,
R.sup.5 is OH or C.sub.1-C.sub.3 hydroxyl. In embodiments, R.sup.3
is H. In embodiments, R.sup.4 is C.sub.1-C.sub.3 alkoxy, such as
methoxy. In embodiments, R.sup.6 is C.sub.1-C.sub.3 alkyl, such as
butyl. In embodiments, R.sup.1 is C.sub.1-C.sub.3 hydroxyl. In some
embodiments where R.sup.2 is
##STR00098##
R.sup.7, R.sup.8 and R.sup.9 may each independently be OH or
C.sub.1-C.sub.3 alkoxy. For example, R.sup.7 may be OH and R.sup.8
and R.sup.9 may each independently be C.sub.1-C.sub.3 alkoxy, such
as methoxy. In some embodiments where R.sup.2 is
##STR00099##
R.sup.3 is OH, C.sub.1-C.sub.3 hydroxyl, or C.sub.1-C.sub.3 alkoxy.
In some embodiments where R.sup.2 is
##STR00100##
R.sup.5 is H. In some embodiments where R.sup.2 is
##STR00101##
R.sup.6 is C.sub.1-C.sub.3 alkoxy, such as methoxy. In some
embodiments where R.sup.2 is
##STR00102##
R.sup.1 is C.sub.1-C.sub.3 alkoxy, such as methoxy. In some
embodiments where R.sup.2 is
##STR00103##
R.sup.4 is H.
[0376] In embodiments, a compound according to Formula L is a
compound having the following structure:
##STR00104##
[0377] where: [0378] R.sup.1, R.sup.3, R.sup.4, R.sup.5 and R.sup.6
are each independently H, OH, C.sub.1-C.sub.3 hydroxyl or
C.sub.1-C.sub.3 alkoxy; and [0379] R.sup.7, R.sup.8 and R.sup.9 are
each independently OH, C.sub.1-C.sub.3 hydroxyl or C.sub.1-C.sub.3
alkoxy.
[0380] In embodiments of a compounds according to Formula L',
R.sup.7, R.sup.8 and R.sup.9 are each independently OH or
C.sub.1-C.sub.3 alkoxy. In embodiments, R.sup.7 is OH and R.sup.8
and R.sup.9 are each independently C.sub.1-C.sub.3 alkoxy, such as
methoxy. In embodiments, R.sup.3 is OH, C.sub.1-C.sub.3 hydroxyl,
or C.sub.1-C.sub.3 alkoxy. In embodiments, R.sup.5 is H. In
embodiments, R.sup.6 is C.sub.1-C.sub.3 alkoxy, such as methoxy. In
embodiments, R.sup.1 is C.sub.1-C.sub.3 alkoxy, such as methoxy. In
embodiments, R.sup.4 is H.
[0381] Group M Compound
[0382] In embodiments, a bioactive, taste modulating, or salty
taste modulating compound is a compound having the following
structure:
##STR00105##
[0383] Group N Compound
[0384] In embodiments, a bioactive, taste modulating, or salty
taste modulating compound is a compound having the following
structure:
##STR00106##
[0385] Group O Compound
[0386] In embodiments, a bioactive, taste modulating, or salty
taste modulating compound is a compound having the following
structure:
##STR00107##
[0387] Group P Compounds
[0388] Group P1 Compounds
[0389] In embodiments, a bioactive, taste modulating, or salty
taste modulating compound is a compound having the following
structure:
##STR00108##
[0390] where: [0391] X is CH or CH.sub.2; [0392] Y is CH or C, with
the caveat that if Y is C, then X is CH; [0393] R.sup.1 is H,
or
[0393] ##STR00109## [0394] where R.sup.5 is OH, C(O)OH, or
OC(O)R.sup.6, where R.sup.6 is a C.sub.1-C.sub.3 alkyl; [0395]
R.sup.2 and R.sup.3 are independently H, or substituted with
hydroxyl or unsubstituted saturated or unsaturated branched or
straight C.sub.1-C.sub.6 alkoxy; and [0396] R.sup.4 is H, or a
saturated or unsaturated branched or straight C.sub.1-C.sub.6
alkyl.
[0397] In embodiments, at least one of R.sup.2 or R.sup.3 is H. In
embodiments, both R.sup.2 and R.sup.3 are H. In embodiments, at
least one of R.sup.2 and R.sup.3 is a substituted saturated or
unsaturated branched or straight C.sub.1-C.sub.6 alkoxy substituted
with at least one hydroxyl group. In embodiments, both R.sup.2 and
R.sup.3 are independently selected from a substituted saturated or
unsaturated branched or straight C.sub.1-C.sub.6 alkoxy substituted
with at least one hydroxyl group. For example, at least one of
R.sup.2 and R.sup.3 can be methoxy. In embodiments, at least one of
R.sup.2 and R.sup.3 is unsaturated. In embodiments, at least one of
R.sup.2 and R.sup.3 is branched. In embodiments, R.sup.2 is a
straight unsubstituted saturated C.sub.1-C.sub.3 alkoxy; and
R.sup.3 is a branched unsubstituted, unsaturated C.sub.3-C.sub.6
alkoxy.
[0398] In embodiments, R.sup.4 is saturated or unsaturated branched
or straight C.sub.1-C.sub.6 alkyl. For example, R.sup.4 can be
C.sub.5 alkyl. In embodiments, R.sup.4 is unsaturated. In
embodiments, R.sup.4 is CH(CH.sub.3).sub.2CHCH.sub.2.
[0399] Group P2 Compounds
[0400] In embodiments, a bioactive, taste modulating, or salty
taste modulating compound is a compound having the following
structure:
##STR00110##
[0401] where [0402] X is selected from NH, O, C(O), CR.sup.5 or
CR.sup.5R.sup.6, where R.sup.5 and R.sup.6 are independently
selected from H, OH, a straight or branched C.sub.1 to C.sub.6
hydroxyl, or a C.sub.1 to C.sub.6 alkyl; and [0403] Y, and Z are
independently selected from O, CR.sup.5, CR.sup.5R.sup.6, where
R.sup.5 and R.sup.6 are independently selected from H, OH, a
straight or branched C.sub.1 to C.sub.6 hydroxyl, or a C.sub.1 to
C.sub.6 alkyl, or
[0403] ##STR00111## [0404] with the proviso that (i) no more than
two of X, Y and Z and are O, and (ii) if Y is [0405] CR.sup.5 then
X or Z is also CR.sup.5; [0406] R.sup.1 is H, C.sub.1-C.sub.3
alkoxy, C(O)R.sup.7, where R.sup.7 is a C.sub.1 to C.sub.6 straight
or branched alkyl, or
[0406] ##STR00112## [0407] where R.sup.8, R.sup.9 and R.sup.10 are
independently selected from: H, OH, C.sub.1 to C.sub.3 hydroxyl,
C.sub.1 to C.sub.3 alkoxy, or C.sub.3 to C.sub.8 alkyl; [0408]
R.sup.2 is H, OH, or
[0408] ##STR00113## [0409] where R.sup.11 is H, OH, or C.sub.1 to
C.sub.3 hydroxyl; [0410] R.sup.3 is H, C.sub.1-C.sub.3 alkoxy, or
together with R.sup.4 form a six membered ring having an oxygen
heteroatom to form a compound having a structure of:
[0410] ##STR00114## [0411] R.sup.4 is H, C.sub.1 to C.sub.3 alkoxy,
or together with R.sup.3 forms the structure above.
[0412] In embodiments, X is CR.sup.5R.sup.6. In embodiments, X is
C(OH)(CH.sub.2CH.sub.2CH.sub.2CH.sub.3). In embodiments, X is O. In
embodiments, X is CH.sub.2.
[0413] In embodiments, Y is O. In embodiments, Y is
CR.sup.5R.sup.6, where R.sup.5 and R.sup.6 are H and a branched
C.sub.1 to C.sub.6 hydroxyl, such as C(CH.sub.3)(CH.sub.3)OH. In
embodiments, Y is CH.
[0414] In embodiments, Z is C(O). In embodiments, Z is CH.sub.2. In
embodiments, Z is O.
[0415] In embodiments, R.sup.1 is
##STR00115##
In embodiments,
[0416] R1 is a C.sub.1-C.sub.3 alkoxy. In embodiments, R.sup.1 is
C(O)R.sup.7, where R.sup.7 is a C.sub.1 to C.sub.6 straight or
branched alkyl.
[0417] In embodiments, R.sup.7 is a branched C.sub.3 alkyl.
[0418] In embodiments, R.sup.2 is H. In embodiments, R.sup.2 is OH.
In embodiments, R.sup.2 is
##STR00116##
[0419] In embodiments, R.sup.3 together with R.sup.4 form a six
membered ring having an oxygen heteroatom to form a compound having
the structure:
##STR00117##
[0420] In embodiments, R.sup.3 is H. In embodiments, R.sup.3 is a
C.sub.1-C.sub.3 alkoxy. In embodiments, R.sup.4 is H.
[0421] In embodiments, X is NH.
[0422] In embodiments, Z is
##STR00118##
[0423] Group P3 Compounds
[0424] In embodiments, a bioactive, taste modulating, or salty
taste modulating compound is a compound having the following
structure:
##STR00119## [0425] where [0426] Y is independently selected from
CR.sup.5, CR.sup.5R.sup.6, where R.sup.5 and R.sup.6 are
independently selected from H, OH, a straight or branched C.sub.1
to C.sub.6 hydroxyl, or a C.sub.1 to C.sub.6 alkyl; [0427] R.sup.1
is H, C.sub.1-C.sub.3 alkoxy, C(O)R.sup.7, where R.sup.7 is a
C.sub.1 to C.sub.6 straight or branched alkyl, or
[0427] ##STR00120## [0428] where R.sup.8, R.sup.9 and R.sup.10 are
independently selected from: H, OH, C.sub.1 to C.sub.3 hydroxyl,
C.sub.1 to C.sub.3 alkoxy, or C.sub.3 to C.sub.8 alkyl; [0429]
R.sup.2 is H or
[0429] ##STR00121## [0430] where R.sup.11 is H, OH, or C.sub.1 to
C.sub.3 hydroxyl; [0431] R.sup.3 is H, C.sub.1-C.sub.3 alkoxy, or
together with R.sup.4 form a six membered ring having an oxygen
heteroatom to form a compound having a structure of:
[0431] ##STR00122## [0432] R.sup.4 is H, C.sub.1 to C.sub.3 alkoxy,
or together with R.sup.3 forms the structure above.
[0433] In embodiments, R.sup.1 is C.sub.1 to C.sub.3 alkoxy. In
embodiments, R.sup.1 is H. In embodiments, R.sup.2 is H. In
embodiments, R.sup.3 is H. In embodiments, R.sup.4 is H.
[0434] Group P4 Compounds
[0435] In embodiments, a bioactive, taste modulating, or salty
taste modulating compound is a compound having the following
structure:
##STR00123##
[0436] where [0437] R.sup.1 is H or a saturated or unsaturated
C.sub.1 to C.sub.6 alkyl; [0438] R.sup.2 is H or a C.sub.1 to
C.sub.3 alkoxy; and [0439] R.sup.3 is H or
[0439] ##STR00124## [0440] where R.sup.4, R.sup.5, [0441] R.sup.6,
R.sup.7, and R.sup.8 are independently selected from: H, OH,
C.sub.1 to C.sub.3 hydroxyl, C.sub.1 to C.sub.3 alkoxy, and C.sub.1
to C.sub.3 alkyl; and [0442] X is NH or O.
[0443] In embodiments, R.sup.1 is CH.sub.2CHC.dbd.(CH.sub.3).sub.2.
In embodiments, R.sup.1 is H. In embodiments, R.sup.2 is methoxy.
In embodiments, R.sup.2 is H. In embodiments, R.sup.3 is H. In
embodiments, R.sup.3 is
##STR00125##
[0444] Group P5 Compound
[0445] In embodiments, a bioactive, taste modulating, or salty
taste modulating compound is a compound having the following
structure:
##STR00126##
[0446] Group Q Compounds
[0447] Group Q1 Compounds
[0448] In embodiments, a bioactive, taste modulating, or salty
taste modulating compound is a compound having the following
structure:
##STR00127## [0449] where A is: [0450] a. CR.sup.9 where R.sup.9 is
H, saturated or unsaturated C.sub.1 to C.sub.6 alkyl, C.sub.1 to
C.sub.3 hydroxyl or CHR.sup.10, where R.sup.10 is C.sub.1 to
C.sub.6 alkyl;
[0451] b. CCR.sup.64R.sup.65R.sup.66, where R.sup.64, R.sup.65, and
R.sup.66 are independently selected from: C.sub.1 to C.sub.10
saturated or unsaturated, branched or straight chain alkyl, or
(CH.sub.2).sub.aR.sup.11 where a is zero or 1 and R.sup.11 is H,
OH, or saccharidyl, [0452] c. CR.sup.23, where R.sup.23 is
saturated or unsaturated, substituted with an oxygen or
unsubstituted five membered ring including at least one oxygen
heteroatom, [0453] d. CR.sup.24, where R.sup.24 is
[0453] ##STR00128## [0454] where R.sup.25 and R.sup.26 are
independently selected from H, OH, or C.sub.1 to C.sub.6 branched
or straight hydroxyl, [0455] e. or along with Q and the atoms
attached thereto form a ring structure of formula (Q1A) below,
[0455] ##STR00129## [0456] where R.sup.27 and R.sup.28 are H, OH,
C.sub.1 to C.sub.3 alkyl, C.sub.1 to C.sub.3 alkoxy, or C.sub.1 to
C.sub.3 hydroxyl; [0457] B is CH.sub.2, or CH, with the caveat that
if B is CH then D is C; [0458] D, E, F, and G are independently
selected from: C, CR.sup.29, where R.sup.29 is H, OH, C.sub.1 to
C.sub.3 alkyl, or C.sub.1 to C.sub.3 hydroxyl, with the caveat that
if D is C, then B is CH; if E is C, then G is C; and if F is C,
then u is zero; [0459] J is C(R.sup.30).sub.vR.sup.31, where v is
zero or 1 and R.sup.30 and R.sup.31 are independently selected from
H, OH, C.sub.1 to C.sub.3 alkyl, C.sub.1 to C.sub.3 hydroxyl,
or
##STR00130##
[0459] where T and X are CH.sub.2 and where f and g are
independently selected from zero (0), 1, or 2, and Z is selected
from CR.sup.32R.sup.33, where R.sup.32 and R.sup.33 are
independently selected from H, OH, C.sub.1 to C.sub.3 hydroxyl, or
C.sub.1 to C.sub.3 alkyl, with the caveat that is v is zero then k
is also zero; [0460] K is CR.sup.5.sub.uR.sup.6, where u is zero or
1 and R.sup.5 and R.sup.6 are independently selected from H, OH,
C.sub.1 to C.sub.3 alkyl, C.sub.1 to C.sub.3 hydroxyl, C.sub.1 to
C.sub.3 alkoxy, with the caveat that if u is zero than F is C;
[0461] L is CR.sup.34.sub.kR.sup.35 where k is zero or 1 and
R.sup.34 and R.sup.35 are independently selected from H, OH,
C.sub.1 to C.sub.3 alkyl, C.sub.1 to C.sub.3 hydroxyl, with the
caveat that if v is zero then k is zero; [0462] M is C(O),
COC(O)R.sup.36 where R.sup.36 is C.sub.1 to C.sub.3 alkyl, CH(OH),
CH(CH.sub.2).sub.jR.sup.37 where j is zero, 1, or 2 and R.sup.37 is
H, OH, or saccharidyl; [0463] Q is C(O), or CR.sup.61R.sup.62,
where R.sup.61 and R.sup.62 are independently selected from H, OH,
C.sub.1 to C.sub.3 alkyl, C.sub.1 to C.sub.3 hydroxyl or along with
A form a five membered ring containing an oxygen hetero atom, or
structure Q1A; [0464] R.sup.1, R.sup.3, and R.sup.7 are
independently selected from H, OH or C.sub.1 to C.sub.3 alkyl;
[0465] R.sup.2, is selected from H, O, OH or C.sub.1 to C.sub.3
alkyl; and [0466] R.sup.4 and R.sup.8 are independently selected
from H, C(O), OH, C.sub.1 to C.sub.3 alkyl, C(O)R.sup.63 where
R.sup.63 is H or C.sub.1 to C.sub.3 alkyl, or OC(O)R.sup.64 where
R.sup.64 is C.sub.1 to C.sub.3 alkyl, or H.
[0467] In embodiments, A is CR.sup.23, wherein R.sup.23 is
saturated or unsaturated, substituted with an oxygen or
unsubstituted five membered ring including at least one oxygen
heteroatom.
[0468] In embodiments, R.sup.23 is
##STR00131##
[0469] In embodiments, A is CR.sup.9, where R.sup.9 is H, saturated
or unsaturated C.sub.1 to C.sub.6 alkyl, C.sub.1 to C.sub.3
hydroxyl or CHR.sup.10, where R.sup.10 is C.sub.1 to C.sub.6
alkyl.
[0470] In embodiments, R.sup.9 is CHR.sup.10. In embodiments,
R.sup.10 is CH.sub.3.
[0471] In embodiments, A along with Q and the atoms attached
thereto form a ring structure of formula (Q1A) below,
##STR00132##
[0472] where R.sup.27 and R.sup.28 are H, OH, C.sub.1 to C.sub.3
alkyl, C.sub.1 to C.sub.3 alkoxy, or C.sub.1 to C.sub.3 hydroxyl.
In embodiments, R.sup.27 and R.sup.28 are each CH.sub.3.
[0473] In embodiments, A is CCR.sup.64R.sup.65R.sup.66, where
R.sup.64, R.sup.65, and R.sup.66 are independently selected from:
C.sub.1 to C.sub.10 saturated or unsaturated, branched or straight
chain alkyl, or (CH.sub.2).sub.aR.sup.11 where a is zero or 1 and
R.sup.11 is H, OH, or
##STR00133## [0474] where a' is zero or 1, R.sup.12, R.sup.13,
R.sup.14, and R.sup.15 are each independently H, OH, CH.sub.3,
C.sub.1-C.sub.3 hydroxyl, COOH, (CH.sub.2).sub.bOC(O)R.sup.16 where
b is zero, 1, 2 or 3 and R.sup.16 is H or C.sub.1-C.sub.3 alkyl, or
(CH.sub.2).sub.dO(CH.sub.2).sub.d'R.sup.17, where d and d' are
independently zero (0) or 1 and R.sup.17 is H or
##STR00134##
[0475] where R.sup.18, R.sup.19, R.sup.20 and R.sup.21 are each
independently H, OH, CH.sub.3, C.sub.1-C.sub.3 hydroxyl, COOH,
(CH.sub.2).sub.eOC(O)R.sup.22 where e is zero, 1, 2 or 3 and
R.sup.22 is H or C.sub.1-C.sub.3 alkyl.
[0476] In embodiments, R.sup.64 is CH.sub.3, R.sup.65 is a C.sub.3
to C.sub.8 unsaturated, branched or chain alkyl, and R.sup.66 is
(CH.sub.2).sub.aO(CH.sub.2).sub.a'R.sup.11 where a and a' are both
zero and R.sup.11 is H or
##STR00135## [0477] where R.sup.12, R.sup.13, and R.sup.15 are each
independently H, OH, CH.sub.3, C.sub.1-C.sub.3 hydroxyl, and
R.sub.14 is (CH.sub.2).sub.dO(CH.sub.2).sub.d'R.sup.17, where d and
d' are independently zero (0) or 1 and R.sup.17 is H or
##STR00136##
[0478] where R.sup.18, R.sup.19, R.sup.29 and R.sup.21 are each
independently H, OH, CH.sub.3, C.sub.1-C.sub.3 hydroxyl, COOH,
OC(O)R.sup.22 where R.sup.22 is H or C.sub.1-C.sub.3 alkyl.
[0479] In embodiments, R.sup.12, R.sup.13, and R.sup.15 are each
independently OH or CH.sub.3.
[0480] In embodiments, R.sup.18, R.sup.19, and R.sup.21 are each
independently OH or H and R.sup.20 is OC(O)CH.sub.3.
[0481] In embodiments, A is CR.sup.24, where R.sup.24 is
##STR00137##
where R.sup.25 and R.sup.26 are independently selected from H, OH,
or C.sub.1 to C.sub.6 branched or straight hydroxyl. In
embodiments, R.sup.26 is OH and R.sup.25 is
C(CH.sub.3).sub.2OH.
[0482] In embodiments, Q is CR.sup.61R.sup.62, where R.sup.61 and
R.sup.62 are independently selected from H, OH, C.sub.1 to C.sub.3
alkyl, C.sub.1 to C.sub.3 hydroxyl. In embodiments, Q is CH.sub.2.
In embodiments, Q is CHOH. In embodiments, Q is C(O).
[0483] In embodiments, B is CH.sub.2. In embodiments, B is CH and D
is C.
[0484] In embodiments, D is CR.sup.29, where R.sup.29 is H, OH,
C.sub.1 to C.sub.3 alkyl, or C.sub.1 to C.sub.3 hydroxyl.
[0485] In embodiments, R.sup.29 is OH. In embodiments, R.sup.29 is
H. In embodiments, R.sup.29 is CH.sub.3.
[0486] In embodiments, E is CR.sup.29, where R.sup.29 is H, OH,
C.sub.1 to C.sub.3 alkyl, or C.sub.1 to C.sub.3 hydroxyl. In
embodiments, R.sup.29 is H. In embodiments, R.sup.29 is CH.sub.3.
In embodiments, E is C and G is C.
[0487] In embodiments, G is CH.
[0488] In embodiments, F is CH. In embodiments, K is CH and F is
C.
[0489] In embodiments, K is CR.sup.5.sub.uR.sup.6, where u is 1 and
R.sup.5 and R.sup.6 are independently selected from C.sub.1 to
C.sub.3 alkyl. In embodiments, R.sup.5 and R.sup.6 are both
CH.sub.3. In embodiments, R.sup.5 and R.sup.6 are both H.
[0490] In embodiments, both J and L are CH. In embodiments, J is
CH.sub.2. In embodiments, J is C(R.sup.30).sub.vR.sup.31, where vi
s 1, R.sup.30 and R.sup.31 is
##STR00138##
where T and X are CH.sub.2 and where f and g are independently
selected from zero, 1, or 2, and Z is CR.sup.32R.sup.33, where
R.sup.32 and R.sup.33 are independently selected from H, OH,
C.sub.1 to C.sub.3 hydroxyl, or C.sub.1 to C.sub.3 alkyl. In
embodiments, f and g are both zero and R.sup.32 and R.sup.33 are OH
and C.sub.1 to C.sub.3 alkyl.
[0491] In embodiments, L is CH.sub.2.
[0492] In embodiments, M is CHOH. In embodiments, M is
CH(CH.sub.2).sub.jR.sup.37 where j is zero, 1, or 2 and R.sup.37 is
H or
##STR00139## [0493] where j' is zero or 1, R.sup.38, R.sup.39,
R.sup.40, and R.sup.41 are each independently selected from H, OH,
CH.sub.3, C.sub.1-C.sub.3 hydroxyl, C.sub.1-C.sub.3 alkoxy, COOH,
(CH.sub.2).sub.mOC(O)R.sup.42 where m is zero, 1, 2 or 3 and
R.sup.42 is H or C.sub.1-C.sub.3 alkyl, or
(CH.sub.2).sub.nO(CH.sub.2).sub.n'R.sup.43, where n and n' are
independently zero or 1 and R.sup.43 is H or
[0493] ##STR00140## [0494] where R.sup.44, R.sup.45, R.sup.46 and
R.sup.47 are each independently H, OH, CH.sub.3, C.sub.1-C.sub.3
hydroxyl, COOH, (CH.sub.2).sub.pOC(O)R.sup.48 where p is zero, 1, 2
or 3 and R.sup.48 is H or C.sub.1-C.sub.3 alkyl, or
(CH.sub.2).sub.qO(CH.sub.2).sub.q'R.sup.49 where q and q' are
independently zero or 1 and R.sup.49 is H or
[0494] ##STR00141## [0495] where R.sup.50, R.sup.51, R.sup.52 and
R.sup.53 are each independently H, OH, CH.sub.3, C.sub.1-C.sub.3
hydroxyl, COOH, (CH.sub.2).sub.rOC(O)R.sup.54 where r is zero, 1, 2
or 3 and R.sup.54 is H or C.sub.1-C.sub.3 alkyl, or
(CH.sub.2).sub.sO(CH.sub.2).sub.s'R.sup.55 where s and s' are
independently zero or 1 and R.sup.55 is H or
[0495] ##STR00142## [0496] where R.sup.56, R.sup.57, R.sup.58 and
R.sup.59 are each independently H, OH, CH.sub.3, C.sub.1-C.sub.3
hydroxyl, COOH, (CH.sub.2).sub.tOC(O)R.sup.60 where t is zero, 1, 2
or 3 and R.sup.60 is H or C.sub.1-C.sub.3 alkyl.
[0497] In embodiments, j and j' are both zero and R.sup.38 is
CH.sub.3; R.sup.39 is OH; R.sup.40 is OCH.sub.3; and R.sup.41 is H.
In embodiments, j and j' are both zero and R.sup.39 is
(CH.sub.2)--O(CH.sub.2).sub.n'R.sup.43, where n and n' are
independently zero or 1 and R.sup.43 is H or
##STR00143## [0498] where R.sup.44, R.sup.45, R.sup.46 and R.sup.47
are each independently H, OH, CH.sub.3, C.sub.1-C.sub.3 hydroxyl,
COOH, (CH.sub.2).sub.pOC(O)R.sup.48 where p is zero, 1, 2 or 3 and
R.sup.48 is H or C.sub.1-C.sub.3 alkyl.
[0499] In embodiments, R.sup.44 is CH.sub.2OH; and R.sup.45,
R.sup.46, and R.sup.47 are all OH.
[0500] In embodiments, M is CH(CH.sub.2).sub.jR.sup.37 where
R.sup.37 is H, OH, or
##STR00144## [0501] where j' is zero or 1, R.sup.38 and R.sup.41
are each independently selected from H, OH, CH.sub.3,
C.sub.1-C.sub.3 hydroxyl, C.sub.1-C.sub.3 alkoxy, COOH,
(CH.sub.2).sub.mOC(O)R.sup.42 where m is zero, 1, 2 or 3 and
R.sup.42 is H or C.sub.1-C.sub.3 alkyl; [0502] where R.sup.39 is
OR.sup.43, where R.sup.43 is H or
[0502] ##STR00145## [0503] where R.sup.44, R.sup.45 and R.sup.47
are each independently H, OH, CH.sub.3, C.sub.1-C.sub.3 hydroxyl,
COOH, (CH.sub.2).sub.pOC(O)R.sup.48 where p is zero, 1, 2 or 3 and
R.sup.48 is H or C.sub.1-C.sub.3 alkyl; and R.sup.46 is
(CH.sub.2).sub.qO(CH.sub.2).sub.q'R.sup.49 where q and q' are
independently zero or 1 and R.sup.49 is H or
[0503] ##STR00146## [0504] where R.sup.50, R.sup.51 and R.sup.53
are each independently H, OH, CH.sub.3, C.sub.1-C.sub.3 hydroxyl,
COOH, (CH.sub.2).sub.rOC(O)R.sup.54 where r is zero, 1, 2 or 3 and
R.sup.54 is H or C.sub.1-C.sub.3 alkyl; and R.sup.52 is OR.sup.55
where R.sup.55 is H or
[0504] ##STR00147## [0505] where R.sup.56, R.sup.57, R.sup.58 and
R.sup.59 are each independently H, OH, CH.sub.3 or C.sub.1-C.sub.3
hydroxyl; and [0506] R.sup.40 is OR.sup.43, and R.sup.43 is H
or
[0506] ##STR00148## [0507] where [0508] R.sup.44, R.sup.45,
R.sup.46 and R.sup.47 are each independently OH, or C.sub.1-C.sub.3
hydroxyl.
[0509] In embodiments, M is CO.
[0510] In embodiments, R.sup.1 is H or C.sub.1-C.sub.3 alkyl. In
embodiments R.sup.1 is CH.sub.3.
[0511] In embodiments, R.sup.2 is H, OH, O, or C.sub.1-C.sub.3
alkyl.
[0512] In embodiments, R.sup.3 is H or C.sub.1-C.sub.3 alkyl.
[0513] In embodiments, R.sup.4 is CH.sub.3. In embodiments, R.sup.4
is CHO.
[0514] In embodiments, R.sup.7 and R.sup.8 are both H. In
embodiments, R.sup.8 is OCOCH.sub.3.
[0515] In embodiments, F is CR.sup.29, where R.sup.29 is H, OH,
C.sub.1-C.sub.3 alkyl, or C.sub.1-C.sub.3 hydroxyl.
[0516] In embodiments, K is CR.sup.5R.sup.6.
[0517] In embodiments, M is C(O), COC(O)R.sup.36, where R.sup.36 is
C.sub.1-C.sub.3 alkyl, CH(CH.sub.2).sub.jR.sup.37 where j is zero
or 1.
[0518] Group Q1B Compounds
[0519] In embodiments, a bioactive, taste modulating, or salty
taste modulating compound is a compound having the following
structure:
##STR00149## [0520] where A is: [0521] a.
CCR.sup.64R.sup.65R.sup.66, where R.sup.64, R.sup.65, and R.sup.66
are independently selected from: C.sub.1 to C.sub.10 saturated or
unsaturated, branched or straight chain alkyl, or
(CH.sub.2).sub.aR.sup.11 where a is zero or 1 and R.sup.11 is H,
OH, or saccharidyl, [0522] b. or along with Q and the atoms
attached thereto form a ring structure of formula (Q1B') below,
[0522] ##STR00150## [0523] where R.sup.27 and R.sup.28 are H, OH,
C.sub.1 to C.sub.3 alkyl, C.sub.1 to C.sub.3 alkoxy, or C.sub.1 to
C.sub.3 hydroxyl; [0524] D, E, F, and G are independently selected
from: CR.sup.29, where R.sup.29 is H, OH, C.sub.1 to C.sub.3 alkyl,
or C.sub.1 to C.sub.3 hydroxyl; [0525] K is CR.sup.5R.sup.6, where
R.sup.5 and R.sup.6 are independently selected from H, or C.sub.1
to C.sub.3 alkyl; [0526] M is CH(CH.sub.2).sub.jR.sup.37 where j is
zero, 1, or 2 and R.sup.37 is H, OH, or saccharidyl; [0527] Q is
CHOH, or along with A form a five membered ring containing an
oxygen heteroatom, or structure II; [0528] R.sup.1, R.sup.2
R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7 and R.sup.8 are
independently selected from H, OH, 0, or C.sub.1 to C.sub.3
alkyl.
[0529] In embodiments, A along with Q and the atoms attached
thereto form a ring structure of formula (Q1B') below,
##STR00151## [0530] where R.sup.27 and R.sup.28 are H, OH, C.sub.1
to C.sub.3 alkyl, C.sub.1 to C.sub.3 alkoxy, or C.sub.1 to C.sub.3
hydroxyl. In embodiments R.sup.27 and R.sup.28 are each
CH.sub.3.
[0531] In embodiments, A is CCR.sup.64R.sup.65R.sup.66, where
R.sup.64, R.sup.65, and R.sup.66 are independently selected from:
C.sub.1 to C.sub.10 saturated or unsaturated, branched or straight
chain alkyl, or (CH.sub.2).sub.aO(CH.sub.2).sub.a'R.sup.11 where a
and a' are independently zero or 1 and R.sup.11 is saccharidyl and
is:
##STR00152## [0532] where a' is zero or 1, R.sup.12, R.sup.13,
R.sup.14, and R.sup.15 are each independently H, OH, CH.sub.3,
C.sub.1-C.sub.3 hydroxyl, COOH, (CH.sub.2).sub.bOC(O)R.sup.16 where
b is zero, 1, 2 or 3 and R.sup.16 is H or C.sub.1-C.sub.3 alkyl, or
(CH.sub.2).sub.dO(CH.sub.2).sub.d'R.sup.17, where d and d' are
independently zero (0) or 1 and R.sup.17 is H or
[0532] ##STR00153## [0533] where R.sup.18, R.sup.19, R.sup.20 and
R.sup.21 are each independently H, OH, CH.sub.3, C.sub.1-C.sub.3
hydroxyl, COOH, (CH.sub.2).sub.eOC(O)R.sup.22 where e is zero, 1, 2
or 3 and R.sup.22 is H or C.sub.1-C.sub.3 alkyl.
[0534] In embodiments, R.sup.64 is CH.sub.3, R.sup.65 is a C.sub.3
to C.sub.8 unsaturated, branched or chain alkyl, and R.sup.66 is
(CH.sub.2).sub.aO(CH.sub.2).sub.a'R.sup.11 where a and a' are both
zero and R.sup.11 is saccharidyl and is:
##STR00154##
[0535] where R.sup.12, R.sup.13, and R.sup.15 are each
independently H, OH, CH.sub.3, C.sub.1-C.sub.3 hydroxyl, and
R.sup.14 is (CH.sub.2).sub.dO(CH.sub.2).sub.d'R.sup.17, where d and
d' are independently zero (0) or 1 and R.sup.17 is H or
##STR00155##
[0536] where R.sup.18, R.sup.19, R.sup.20 and R.sup.21 are each
independently H, OH, CH.sub.3, C.sub.1-C.sub.3 hydroxyl, COOH,
OC(O)R.sup.22 where R.sup.22 is H or C.sub.1-C.sub.3 alkyl.
[0537] In embodiments, R.sup.12, R.sup.13, and R.sup.15 are each
independently OH or CH.sub.3.
[0538] In embodiments, R.sup.18, R.sup.19, and R.sup.21 are each
independently OH or H and R.sup.20 is OC(O)CH.sub.3.
[0539] In embodiments, M is CH(CH.sub.2).sub.jR.sup.37 where j is
zero, 1, or 2 and R.sup.37 is saccharidyl and is:
##STR00156##
[0540] where j' is zero or 1, R.sup.38, R.sup.39, R.sup.40, and
R.sup.41 are each independently selected from H, OH, CH.sub.3,
C.sub.1-C.sub.3 hydroxyl, C.sub.1-C.sub.3 alkoxy, COOH,
(CH.sub.2).sub.mOC(O)R.sup.42 where m is zero, 1, 2 or 3 and
R.sup.42 is H or C.sub.1-C.sub.3 alkyl, or
(CH.sub.2).sub.nO(CH.sub.2).sub.n'R.sup.43, where n and n' are
independently zero (0) or 1 and R.sup.43 is H or
##STR00157##
[0541] where R.sub.44, R.sup.45, R.sup.46 and R.sup.47 each
independently H, OH, CH.sub.3, C.sub.1-C.sub.3 hydroxyl, COOH,
(CH.sub.2).sub.pOC(O)R.sup.48 where p is zero, 1, 2 or 3 and
R.sup.48 is H or C.sub.1-C.sub.3 alkyl, or
(CH.sub.2).sub.qO(CH.sub.2).sub.q'R.sup.49 where q and q' are
independently zero or 1 and R.sup.49 is H or
##STR00158##
[0542] where R.sup.50, R.sup.51, R.sup.52 and R.sup.53 are each
independently H, OH, CH.sub.3, C.sub.1-C.sub.3 hydroxyl, COOH,
(CH.sub.2).sub.rOC(O)R.sup.54 where r is zero, 1, 2 or 3 and
R.sup.54 is H or C.sub.1-C.sub.3 alkyl, or
(CH.sub.2).sub.sO(CH.sub.2).sub.s'R.sup.55 where s and s' are
independently zero or 1 and R.sup.55 is H or
##STR00159##
[0543] where R.sup.56, R.sup.57, R.sup.58 and R.sup.59 are each
independently H, OH, CH.sub.3, C.sub.1-C.sub.3 hydroxyl, COOH,
(CH.sub.2).sub.tOC(O)R.sup.60 where t is zero, 1, 2 or 3 and
R.sup.60 is H or C.sub.1-C.sub.3 alkyl.
[0544] In embodiments, j and j' are both zero and R.sup.38 is
CH.sub.3; R.sup.39 is OH; R.sup.40 is OCH.sub.3; and R.sup.41 is
H.
[0545] In embodiments, j and j' are both zero and R.sup.39 is
(CH.sub.2).sub.nO(CH.sub.2).sub.n'R.sup.43, where n and n' are
independently zero or 1 and R.sup.43 is saccharidyl and is:
##STR00160## [0546] where R.sup.44, R.sup.45, R.sup.46 and R.sup.47
are each independently H, OH, CH.sub.3, C.sub.1-C.sub.3 hydroxyl,
COOH, (CH.sub.2).sub.pOC(O)R.sup.48 where p is zero, 1, 2 or 3 and
R.sup.48 is H or C.sub.1-C.sub.3 alkyl.
[0547] In embodiments, R.sup.44 is CH.sub.2OH; and R.sup.45,
R.sup.46, and R.sup.47 are all OH.
[0548] In embodiments, D is CR.sup.29, where R.sup.29 is C.sub.1 to
C.sub.3 alkyl.
[0549] In embodiments, E is CR.sup.29, where R.sup.29 is C.sub.1 to
C.sub.3 alkyl.
[0550] In embodiments, G is CH.
[0551] In embodiments, F is CH.
[0552] In embodiments, K is CH and F is C.
[0553] In embodiments, K is CR.sup.5.sub.uR.sup.6, where u is 1 and
R.sup.5 and R.sup.6 are independently selected from C.sub.1 to
C.sub.3 alkyl. In embodiments, R.sup.5 and R.sup.6 are both
CH.sub.3.
[0554] In embodiments, R.sup.2, R.sup.4, R.sup.8, and R.sup.9 are
all H.
[0555] In embodiments, R.sup.1 is C.sub.1-C.sub.3 alkyl. In
embodiments, R.sup.1 is H.
[0556] In embodiments, R.sup.3 is O. In embodiments, R.sup.3 is
H.
[0557] Group Q2 Compounds
[0558] In embodiments, a bioactive, taste modulating, or salty
taste modulating compound is a compound having the following
structure:
##STR00161## [0559] where A is C or CR.sup.4, where R.sub.4 is H,
OH, C.sub.1 to C.sub.3 alkyl, with the caveat that if A is C, then
B is CR.sup.6; [0560] B is CR.sup.5.sub.aR.sup.6, where a is zero
(0) or 1, and R.sup.5 and R.sup.6 are independently selected from
H, OH, C.sub.1 to C.sub.3 alkyl, with the caveat that if A is C,
then B is CR.sup.6; [0561] X is H, or along with Y and the atoms
attached thereto form a ring structure having formula (Q2A)
below,
[0561] ##STR00162## [0562] where R.sup.9 and R.sup.10 are
independently selected from O and CH.sub.2; [0563] Z is H or along
with Y and the atoms attached thereto form a ring structure having
formula (Q2B) below,
[0563] ##STR00163## [0564] where R.sup.13 and R.sup.14 are
independently selected from O and CH.sub.2; [0565] Y together with
either X or Z forms a ring structure of formula Q2A or Q2B above;
and [0566] R.sup.1, R.sup.2 and R.sup.3 are independently selected
from H, CH.sub.2, C.sub.1 to C.sub.3 alkyl.
[0567] In embodiments, A is CH.sub.3. In embodiments, R.sup.1 is
CH.sub.2. In embodiments, R.sup.2 is H. In embodiments, R.sup.3 is
H. In embodiments, A is CR.sup.4, where R.sup.4 is C.sub.1 to
C.sub.3 alkyl. In embodiments, B is CH.sub.2.
[0568] In embodiments, X and Y along with the atoms attached
thereto form a ring structure having formula (Q2A) below,
##STR00164##
In embodiments, R.sup.9 is O and R.sup.10 is CH.sub.2.
[0569] In embodiments, Y and Z along with the atoms attached
thereto form a ring structure having formula (Q2B) below,
##STR00165## [0570] where R.sup.13 and R.sup.14 are independently
selected from O and CH.sub.2. In embodiments, R.sup.3 is CH.sub.3.
In embodiments, R.sup.1 is H. In embodiments, R.sup.2 is CH.sub.2.
In embodiments, R.sup.2 is CH.sub.3.
[0571] Group Q3 Compounds
[0572] In embodiments, a bioactive, taste modulating, or salty
taste modulating compound is a compound having the following
structure:
##STR00166## [0573] where A is C or CR.sup.4, where R.sub.4 is H,
OH, C.sub.1 to C.sub.3 alkyl, with the caveat that if A is C, then
B is CR.sup.6; [0574] B is CR.sup.5.sub.aR.sup.6, where a is zero
or 1, and R.sup.5 and R.sup.6 are independently selected from H,
OH, C.sub.1 to C.sub.3 alkyl; [0575] Z is H or CR.sup.11R.sup.12
where R.sup.11 and R.sup.12 are independently selected from H, OH,
C.sub.1 to C.sub.3 alkyl; [0576] R.sup.1, R.sup.2 and R.sup.3 are
independently selected from H, CH.sub.2, or a saturated or
unsaturated C.sub.1 to C.sub.6 alkyl; and [0577] R.sup.9 and
R.sup.10 are independently selected from O or CH.sub.2.
[0578] In embodiments, A is CCH.sub.3. In embodiments, B is
CH.sub.2. In embodiments, Z is H. In embodiments, R.sup.1 is
CH.sub.2. In embodiments, R.sub.2 is H. In embodiments, R.sub.3 is
H. In embodiments, R.sup.9 is O. In embodiments, R.sup.10 is
CH.sub.2.
[0579] Group R Compounds
[0580] Group R1 Compounds
[0581] In embodiments a bioactive, taste modulating, or salty taste
modulating compound is a compound having the following
structure:
##STR00167##
[0582] where R.sup.1 is OH or saccharidyl;
[0583] R.sup.2 and R.sup.3 are independently H, OH, and COOH;
and
[0584] R.sup.4 is C.sub.3-C.sub.14 saturated or unsaturated alkyl
optionally substituted with one or more hydroxyls.
[0585] In embodiments R.sup.1 is OH. In embodiments R.sup.2 is H.
In embodiments, R.sup.2 is OH. In embodiments, R.sup.3 is H. In
embodiments, R.sup.3 is COOH. In embodiments, R.sup.4 is C.sub.9 to
C.sub.13 unsaturated alkyl. In embodiments, R.sup.4 is C.sub.9 to
C.sub.13 unsaturated alkyl with at least one hydroxyl. In
embodiments, R.sup.4 is C.sub.10 to C.sub.12 alkyl with at least
two double bonds, such as C.sub.11 with at least two double bonds.
In embodiments, R.sup.4 is C.sub.11 with three double bonds. In
embodiments, R.sup.4 is C.sub.11 with three double bonds and one
hydroxyl. In embodiments, R.sup.4 is C.sub.3 to C.sub.7 with at
least one double bond.
[0586] In embodiments of a compound according to Formula R.sub.1 is
a compound where R.sup.2 and R.sup.3 are independently H, OH, and
COOH; and R.sup.4 is C.sub.3-C.sub.10 saturated or unsaturated
alkyl optionally substituted with one or more hydroxyls. In
embodiments, R.sup.2 is OH. In embodiments, R.sup.3 is COOH. In
embodiments, R.sup.4 is C.sub.3 to C.sub.7 with at least one double
bond.
[0587] Group R2 Compounds
[0588] In embodiments a bioactive, taste modulating, or salty taste
modulating compound is a compound having the following
structure:
##STR00168##
[0589] where
[0590] A is (CH.sub.2).sub.x, where x is 0 or 1;
[0591] R.sup.5 is saccharidyl;
[0592] R.sup.2 and R.sup.3 are independently H, OH, and COOH;
and
[0593] R.sup.4 is C.sub.8-C.sub.16 saturated or unsaturated alkyl
optionally substituted with one or more hydroxyls.
[0594] In embodiments, a compound of formula R.sub.2 the following
structure:
##STR00169##
[0595] where
[0596] A, D, E and G are independently (CH.sub.2).sub.x, where x is
0 or 1;
[0597] R.sup.1 is H or saccharidyl;
[0598] R.sup.2 and R.sup.3 are independently H, OH, and COOH;
and
[0599] R.sup.4 is C.sub.8-C.sub.16 saturated or unsaturated alkyl
optionally substituted with one or more hydroxyls.
[0600] In embodiments, R.sup.1 is H. In embodiments, R.sup.2 is H.
In embodiments, R.sup.3 is H. In embodiments, R.sup.4 is C.sub.8 to
C.sub.14 unsaturated alkyl optionally substituted with one or more
hydroxyls, such as C.sub.10 to C.sub.13 unsaturated alkyl
optionally substituted with one or more hydroxyls. In embodiments,
R.sup.4 is C.sub.11 unsaturated alkyl optionally substituted with
one or more hydroxyls. In embodiments, R.sup.4 is C.sub.ii
unsaturated alkyl with one double bond optionally substituted with
one or more hydroxyls. In embodiments, x is one in A and E; and x
is zero in D and E.
[0601] Group R3 Compounds
[0602] In embodiments a bioactive, taste modulating, or salty taste
modulating compound is a compound having the following
structure:
##STR00170##
[0603] where [0604] R.sup.1 is H, or OH; [0605] R.sup.2 and R.sup.3
are independently H, OH, or CH.sub.2OH; [0606] X is O or CHOH;
[0607] Y is C.dbd.O or CH.sub.2; and [0608] R.sup.4 is
C.sub.3-C.sub.12 unsaturated alkyl.
[0609] In embodiments, R.sup.1 is OH. In embodiments, R.sup.2 is H.
In embodiments, X is CHOH. In embodiments, Y is CH.sub.2. In
embodiments, R.sup.3 is H.
[0610] In embodiments, R.sup.4 is a C.sub.3 to C.sub.7 unsaturated
alkyl. In embodiments, R.sup.4 is a C.sub.5 unsaturated alkyl. In
embodiments, R.sup.4 is a C.sub.5 alkyl with one double bond.
[0611] In embodiments, R.sup.3 is OH.
[0612] In embodiments, R.sup.4 is a C.sub.8 to C.sub.12 unsaturated
alkyl. In embodiments, R.sup.4 is a C.sub.10 unsaturated alkyl. In
embodiments, R.sup.4 is a C.sub.10 alkyl with one double bond.
[0613] Group R4 Compounds
[0614] In embodiments a bioactive, taste modulating, or salty taste
modulating compound is a compound having the following
structure:
##STR00171## [0615] where [0616] X is O or NH; [0617] R.sup.1 is H,
OH, or CH.sub.2OH; [0618] R.sup.2 is H or OCOR.sup.5, wherein
R.sup.5 is a C.sub.1-C.sub.3 alkyl; and [0619] R.sup.3 is H or
C.sub.1-C.sub.10 saturated or unsaturated alkyl.
[0620] In embodiments, X is O. In embodiments, R.sup.1 is OH. In
embodiments, R.sup.2 is OCOR.sup.5. In some embodiments where
R.sup.2 is OCOR.sup.5, R.sup.5 is CH.sub.3. In embodiments, R.sup.3
is C.sub.5 to C.sub.9 saturated or unsaturated alkyl, such as
C.sub.7 unsaturated alkyl. In embodiments, R.sup.3 is C.sub.7 alkyl
with one double bond.
[0621] In embodiments, X is NH. In some embodiments where X is NH,
R.sup.1 and R.sup.2 are both H. In some embodiments where X is NH,
R.sup.3 is H.
[0622] Group S Compounds
[0623] In embodiments a bioactive, taste modulating, or salty taste
modulating compound is a compound having the following
structure:
##STR00172## [0624] where: [0625] X and Y are each independently
C.sub.7-C.sub.20 straight or branched chain unsaturated alkyl
unsubstituted or substituted with one or more OH; [0626] A is
saccharidyl; and [0627] R.sup.10 and R.sup.11 are each
independently H, OH or saccharidyl.
[0628] In embodiments a compound according to Formula S has the
following structure:
##STR00173## [0629] where: [0630] a, b, d, e, f and g are each
independently zero or 1; [0631] X and Y are each independently
C.sub.7-C.sub.20 straight or branched chain unsaturated alkyl
unsubstituted or substituted with one or more OH; [0632] R.sup.1,
R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, and
R.sup.9 are each independently H, OH, CH.sub.3, CH.sub.2CH.sub.3,
and CH.sub.2OH; and [0633] R.sup.10 and R.sup.11 are each
independently H, OH or saccharidyl.
[0634] In embodiments, one or both of R.sup.10 and R.sup.11 are
saccharidyl and are independently
##STR00174## [0635] where [0636] i, j and k are each independently
zero or 1, and [0637] R.sup.12, R.sup.13, R.sup.14, R.sup.15,
R.sup.16, R.sup.17 and R.sup.18 are each independently H, OH,
CH.sub.3, CH.sub.2CH.sub.3 and CH.sub.2OH.
[0638] In embodiments, X and Y are each independently
C.sub.8-C.sub.16 straight or branched chain unsaturated alkyl
unsubstituted or substituted with one or more OH and having 2 to 6
double bounds. In embodiments, X and Y are each independently
C.sub.10-C.sub.15 straight or branched chain unsaturated alkyl
unsubstituted or substituted with one or more OH and having 2 to 4
double bounds.
[0639] In embodiments a compound according to Formula S has the
following structure:
##STR00175## [0640] where a, b, d, e, f and g, and R.sup.1,
R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8,
R.sup.9, R.sup.10 and R.sup.11 are as defined above; and wherein
[0641] R.sup.19, R.sup.20, R.sup.21, R.sup.22 and R.sup.23 are each
independently H, CH.sub.3 or OH.
[0642] In embodiments a compound according to Formula S has the
following structure:
##STR00176## [0643] where R.sup.19, R.sup.20, R.sup.23 and R.sup.24
are each independently H, CH.sub.3 or OH.
[0644] Group T Compounds
[0645] In embodiments, a bioactive, taste modulating, or salty
taste modulating compound is a compound having the following
structure:
##STR00177## [0646] where: [0647] R.sup.1 is H, or COR.sup.4 where
R.sup.4 is H, or saturated or unsaturated C.sub.1-C.sub.6 straight
or branched alkyl; and [0648] R.sup.2, R.sup.3, R.sup.a, R.sup.b,
R.sup.c, R.sup.d, R.sup.e, R.sup.f, R.sup.g, R.sup.h, R.sup.i, and
R.sup.j are independently selected from H, or saturated or
unsaturated C.sub.1-C.sub.3 alkyl.
[0649] In embodiments, R.sup.2, R.sup.3, R.sup.a, R.sup.b, R.sup.c,
R.sup.d, R.sup.e, R.sup.f, R.sup.g, R.sup.h, R.sup.i, and R.sup.j
are independently selected from H, or saturated or unsaturated
C.sub.1-C.sub.3 alkyl with the caveat that saturated or unsaturated
C.sub.1-C.sub.3 alkyl substituents are not directly adjacent each
other.
[0650] In embodiments, R.sup.2 is a saturated or unsaturated
C.sub.1-C.sub.3 alkyl, such as methyl. In embodiments, R.sup.3 is a
saturated or unsaturated C.sub.1-C.sub.3 alkyl, such as methyl. In
embodiments, R.sup.2 is CH.sub.3 and R.sup.3 is CH.sub.3.
[0651] In embodiments, R.sup.1 is H. In embodiments, R.sup.1 is
COCH.sub.3. In embodiments, R.sup.1 is COR.sup.4 and R.sup.4 is
##STR00178##
where R.sup.5 and R.sup.6 are independently selected from H, or
saturated or unsaturated C.sub.1-C.sub.4.
[0652] In embodiments, R.sup.5 and R.sup.6 are both CH.sub.3.
[0653] In embodiments a compound according to Formula T is a
compound where (i) R.sup.2, R.sup.3, R.sup.a, R.sup.b, R.sup.c,
R.sup.d, R.sup.e, R.sup.f, R.sup.g, R.sup.h, R.sup.i, and R.sup.j
are independently selected from H, or saturated or unsaturated
C.sub.1-C.sub.3 alkyl; and (ii) R.sup.7 is H or saturated or
unsaturated C.sub.1-C.sub.3 alkyl. In such embodiments, R.sup.7 may
be CH.sub.3. R.sup.2, R.sup.3, R.sup.a, R.sup.b, R.sup.c, R.sup.d,
R.sup.e, R.sup.f, R.sup.g, R.sup.h, R.sup.i, and R.sup.j may
independently be selected from H, or saturated or unsaturated
C.sub.1-C.sub.3 alkyl with the caveat that saturated or unsaturated
C.sub.1-C.sub.3 alkyl substituents are not directly adjacent each
other. R.sup.2 may be a saturated or unsaturated C.sub.1-C.sub.3
alky, such as methyl. R.sup.3 may be a saturated or unsaturated
C.sub.1-C.sub.3 alkyl, such as methyl. In some of such embodiment,
R.sup.2 is CH.sub.3 and R.sup.3 is CH.sub.3.
[0654] In embodiments, a bioactive, taste modulating, or salty
taste modulating compound is a compound having the following
structure:
##STR00179##
[0655] where [0656] R.sup.2, R.sup.3, R.sup.a, R.sup.b, R.sup.c,
R.sup.d, R.sup.e, R.sup.f, R.sup.g, R.sup.h, R.sup.i, and R.sup.j
are independently selected from H, or saturated or unsaturated
C.sub.1-C.sub.3 alkyl; and [0657] R.sup.7 is H or saturated or
unsaturated C.sub.1-C.sub.3 alkyl.
[0658] Group U Compounds
[0659] In embodiments, a bioactive, taste modulating, or salty
taste modulating compound is a compound having the following
structure:
##STR00180##
[0660] where: [0661] R.sup.1 is H, OH, or C.sub.1-C.sub.3 alkoxy;
[0662] R.sup.a, R.sup.b, R.sup.c, R.sup.d, and R.sup.e are each
independently selected from: H, OH, or C.sub.1-C.sub.3 alkoxy;
[0663] R.sup.2 is H, OH, C.sub.1-C.sub.3 alkoxy, or R.sup.2 and
R.sup.3 together form
[0663] ##STR00181## [0664] to form a compound of the following
structure
[0664] ##STR00182## [0665] R.sup.3 is H, OH, C.sub.1-C.sub.3
alkoxy, or R.sup.2 and R.sup.3 together form a ring structure as
indicated above; [0666] R.sup.4 is H, OH, or C.sub.1-C.sub.3
alkoxy; [0667] X is O or CH; and [0668] Y is O or CR.sup.5, where
R.sup.5 is H or
[0668] ##STR00183## [0669] where [0670] R.sup.6, R.sup.7, and
R.sup.8 are each independently selected from: H, OH, or
C.sub.1-C.sub.3 alkoxy; [0671] R.sup.f, R.sup.g, R.sup.h, R.sup.i,
R.sup.j, and R.sup.k are each independently selected from: H, OH,
or C.sub.1-C.sub.3 alkoxy, [0672] wherein the at least one compound
of formula U is present in the food product in an amount sufficient
to enhance a perception of saltiness of the food product.
[0673] In embodiments, R.sup.1 is H. In embodiments, R.sup.1 is
--OCH.sub.3. In embodiments, R.sup.2 is H. In embodiments, R.sup.3
is H. In embodiments, both R.sup.2 and R.sup.3 are H.
[0674] In embodiments where R.sup.2 and R.sup.3 together form
##STR00184##
to form a compound of the following structure
##STR00185##
R.sup.4 is H.
[0675] In embodiments where R.sup.2 and R.sup.3 form
##STR00186##
to form a compound of the following structure
##STR00187##
R.sup.4 is H.
[0676] In embodiments, R.sup.a, R.sup.b, R.sup.c, R.sup.d, and
R.sup.e are independently H or OH.
[0677] In embodiments, Y is O. In embodiments, Y is CR.sup.5, where
CR.sup.5 is
##STR00188##
R.sup.6 may be OH. R.sup.7 may be OH. R.sup.8 may be OH. R.sup.f,
R.sup.g, R.sup.h, R.sup.i, R.sup.j, or R.sup.k may independently be
H or OH.
[0678] In embodiments, a compound according to Formula U is a
compound having the following structure:
##STR00189##
[0679] where: [0680] R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.6,
R.sup.7, and R.sup.8 are each independently H, OH, or
C.sub.1-C.sub.3 alkoxy; [0681] X and Z are each independently O or
CH; and [0682] R.sup.a, R.sup.b, R.sup.c, R.sup.d, R.sup.e,
R.sup.f, R.sup.g, R.sup.h, R.sup.i, R.sup.j, and R.sup.k are each
independently H, OH, or C.sub.1-C.sub.3 alkoxy.
[0683] In embodiments, a compound of Formula UA is a compound where
R.sup.1 is OH or C.sub.1-C.sub.3 alkoxy. In embodiments, R.sup.2 is
H. In embodiments, R.sup.3 is OH or C.sub.1-C.sub.3 alkoxy. In
embodiments, R.sup.4 is OH or C.sub.1-C.sub.3 alkoxy. In
embodiments, R.sup.6 is OH or C.sub.1-C.sub.3 alkoxy. In
embodiments, R.sup.7 is OH or C.sub.1-C.sub.3 alkoxy. In
embodiments, R.sup.a, R.sup.b, R.sub.c, R.sup.d, R.sup.e, R.sup.f,
R.sup.g, R.sup.h, R.sup.i, R.sup.j, and R.sup.k are each
independently H or OH. In embodiments, R.sup.a, R.sup.b, R.sub.c,
R.sup.d, R.sup.e, R.sup.f, R.sup.g, R.sup.h, R.sup.i, R.sup.j, and
R.sup.k are each H. In embodiments, X is O. In embodiments, Z is
O.
[0684] For purpose of convenience, Table 2A lists the initially
selected 99 compounds (with compounds 12 and 20 being the same
compound isolated from different sources) and indicates which
categories and subcategories, if appropriate, into which each of
the compounds falls. Table 2B lists the categories and the compound
that fall within each category.
TABLE-US-00002 TABLE 2A Listing of compounds according to category
Compound Category Sub-Categories 1 A -- 2 -- 3 -- 4 -- 5 -- 6 -- 7
-- 8 A and B B1, B3 9 A -- 10 B B1, B3 11 B1, B3 12 B1, B3 13 B1 14
B1' 15 B1' 16 B2, B4 17 B2, B4 18 B1' 19 B1, B3 20 B1, B3 21 B1 22
B1' 23 C C'', C''' 24 C'', C''', C'''' 25 C'', C''' 26 C', C''' 27
C' 28 -- 29 D -- 30 -- 31 -- 32 E -- 33 -- 34 F -- 35 F', F'' 36 F'
37 Q Q1, Q1A, Q1B 38 Q1, Q1B 39 F F' 40 G -- 41 H -- 42 F -- 43 --
44 I -- 45 -- 46 -- 47 I' 48 J J1, J1'' 49 J1, J1'' 50 J1, J1', J2
51 J2 52 K -- 53 L 54 55 L' 56 M -- 57 N -- 58 O -- 59 P P5 60 P2,
P2' 61 P4 62 P1 63 P1 64 P1 65 P1 66 P4 67 P2 68 P2, P3 69 P2 70 P1
71 P1 72 P1 73 Q Q1 74 Q1 75 Q1 76 Q1 77 Q1 78 Q1 79 Q2, Q2A, Q3
80a Q2, Q2B 80b Q2, Q2B 81 R R1 82 R3 83 R4 84 R4 85 R1 86 R1 87 R3
88 R1 89 R1 90 R2 91 S -- 92 -- 93 T -- 94 T2 95 -- 96 U U' 97 UA
98 U'' 99 --
TABLE-US-00003 TABLE 2B Listing of compounds according to category
Category Compounds A 1-9 B 8, 10-22 C 23-28 D 29-31 E 32, 33 F
34-36, 39, 42, 43 G 40 H 41 I 44-47 J 48-51 K 52 L 53-55 M 56 N 57
O 58 P 59-72 Q 37, 38, 73-79, 80a, 80b R 81-90 S 91, 92 T 93-95 U
96-99
[0685] As can be seen from the structures of the compounds provided
above, many of the compounds have structural similarities.
Accordingly, it is believed that structural derivatives of the
specific compounds presented above would also have the ability to
elicit the perception of saltiness or enhance saltiness.
Combinations of the compounds could also serve to elicit the
perception of saltiness or enhance saltiness. In addition or
alternatively, one or more of the compounds may elicit the
perception of other simple or complex flavors, other than or in
addition to saltiness.
[0686] Many of the structural similarities between the compounds
are reflected in the compounds of Formulas A through U, as well as
subclasses thereof, presented above. It will be further understood,
based on the compounds identified herein, that one or more of
gingerols, alkyl substituted phenols, acridone alcaloids, labdanes,
primaranes, saponines, neolignans, pentacyclic triterpenes,
2,2'-cyclolignans, dibenzylbutane lignans, bicyclic triterpenes,
phloroglucines, carylophyllenes, beta-carbolines, limnoids,
cumarines, cardanolide steroids, fatty acids, and derivatives may
be candidates for taste modulating compounds. It will be further
understood that other structural similarities of the compounds
presented herein may be exploited to develop taste modulating
compounds.
[0687] By way of example, many of the compounds presented herein
have unsaturated carbon chains of at least 11 carbons with attached
hydroxyl groups and may be amphiphilic, with hydrophobic head
portions and hydrophobic tails. Other compounds having, for example
C.sub.5-C.sub.20 alkane or alkene tails may elicit or enhance
saltiness. Similarly, other compounds with differently substituted
carboxyl or hydroxyl groups may elicit or enhance the perception of
saltiness.
[0688] Many compounds presented herein have large numbers of cyclic
groups having a central portion that may be hydrophobic and
peripheral regions that may be hydrophilic. More specifically, some
compounds include pentacyclohexane with hydroxyl groups, attached
sugars and at least one ester linkage. Substitution of the central
hydrophobic ring structure with, for example, C.sub.5-C.sub.20
hydrophobic alkyl or alkene groups, may result in compounds that
may elicit or enhance saltiness. Alternative substitution of
hydroxyl groups at the peripheral regions or substitution with
carboxylic groups may also result in compounds that elicit or
enhance the perception of saltiness.
[0689] Many of the compounds presented above have one or more
aromatic ring structures, with some being substituted and some
being unsubstituted. Similar substitution or unsubstitution of such
compounds may result in compounds that enhance or elicit
saltiness.
[0690] A plurality of compounds presented herein include saturated
carbon chains of at least 9 carbons and one oxygen containing group
such as hydroxyl, carbonyl, carboxyl, or ester. Other compounds
having unsaturated carbon chains of, for example, 5 to 15 carbons
and an oxygen group may have similar effects with regard to salty
taste.
[0691] Many compounds presented herein have at least one phenol
group with an ether group and a carbon side chain comprising at
least seven carbons. Other similar compounds may have similar
effects with regard to salty taste.
[0692] A number of compounds presented herein have a benzyl
heterocyclic furan with various attached groups containing
unsaturated carbon linkages and at least one carbonyl group. Other
similar compounds may have similar activity with regard to salty
taste.
[0693] A plurality of compounds presented above contain a
cyclopentaphenthrene group. Other compounds having a
cyclopentaphenthrene and similar substituents may have similar
activity with regard to salty taste.
[0694] A number of the compounds presented herein include a
benzopyranone group. Other compounds having a benzopyranone and
similar substituents may have similar activity with regard to salty
taste.
[0695] Some compounds presented above have unsubstituted carbon
chain with a minimum of 13 carbons and at least one carbonyl group.
Other similar compounds may have similar activity with regard to
salty taste.
[0696] A plurality of compounds presented herein have a
methoxymethyltetrahydrobenzo-cyclooctabenzo-dioxole or -annulene
group. Other compounds having such groups may have similar activity
with regard to salty taste.
[0697] A number of compounds presented above have tetracyclohexane
with an attached ester or carbonyl moiety. Other similar compounds
may have similar activity with regard to salty taste.
[0698] Many of the compounds can be classified as lactones,
lignol-like compounds, oxylipins, polyisoprene glycosides,
triterpenoid glycosides, alkylamides, or gamma pyrenes. Other
similar compounds may also elicit or enhance salty taste
perception.
[0699] It will be understood that derivations of the compounds
discussed above are provided for purposes of example and that other
derivatives or derivations may be made based on structural
similarities between the various compounds, resulting in compounds
that elicit or enhance perception of saltiness.
[0700] Evaluation of Salty Taste or Salty Taste Enhancement
[0701] Many of the identified compounds were tested by tasters and
rated for perception of saltiness in combination with reduced
amounts of sodium chloride and were assigned a rating (DAP score)
for saltiness. Briefly, each individual tested compound was placed
in water and in sodium solution to test saltiness and saltiness
enhancement potential. Tests in water were executed in a compound
concentration of 10 ppm. Tests in sodium solution were executed in
compound concentrations of 0.1, 1 and 10 ppm. Two control sodium
solutions with known organoleptic salt intensities were provided as
references for each test. The test for individual compounds was
also conducted using simple broth instead of sodium solution. A
number of compound combinations identified from the Na-solution DAP
test were used for the broth DAP test. Tests were executed with a
trained panel of 9-12 assessors. For Na-solution DAP tests, a DAP
score of greater than 3.1 indicates saltiness or salt enhancement.
The DAP score can be correlated with a sodium reduction potential
by subtracting 3.1 from the DAP score. For example, a DAP score of
4.0 would result in a 9% sodium reduction potential
((4.0-3.1)*10=9%), which means that 9% less sodium may be present
in a food product having the salty compound relative to a
substantially similar food product that does not have the salty
compound while producing a similar saltiness. For broth DAP tests,
a DAP score of greater than 7.6 indicates saltiness or salt
enhancement. The DAP score can be correlated with a sodium
reduction potential by subtracting 7.6 from the DAP score. For
example, a DAP score of 8.5 would result in a 9% sodium reduction
potential ((8.5-7.6)*10=9%), which means that 9% less sodium may be
present in a food product having the salty compound relative to a
substantially similar food product that does not have the salty
compound while producing a similar saltiness.
[0702] A summary of the compounds, the channels for which in vitro
thresholds were identified, and the DAP scores are provided below
in Table 3.
TABLE-US-00004 TABLE 3 Activity of identified compounds in
Na-Solution and in simple broth DAP in DAP in Compound Na-Sol.
Broth 1 3.6 7.8 2 3.5 7.8 3 4.1 8.8 4 3.5 N.T. 5 3.6 N.T. 6 3.8
N.T. 7 3.7 N.T. 8 4 N.T. 9 3.8 N.T. 10 3.9 7.9 11 2.6 8.1 12 4 7.6
13 3.8 7.9 14 3.6 N.T. 15 3.5 8.1 16 3.3 8.0 17 3.6 8.2 18 3.8 8.1
19 N.T. N.T. 20 4 N.T. 21 4 N.T. 22 N.T. N.T. 23 2.9 8.3 24 N.T.
N.T. 25 3.9 N.T. 26 3.4 N.T. 27 3.4 N.T. 28 3.6 N.T. 29 3.5 8.0 30
3.1 N.T. 31 3.2 N.T. 32 3.5 8.1 33 3.4 7.7 34 3.9 7.7 35 3.7 8.1 36
3.9 8.2 37 3.7 8.1 38 3.9 8.1 39 N.T. N.T. 40 3.5 7.8 41 3.9 7.5 42
3.1 8.1 43 3.7 8.0 44 3.8 8.6 45 3.5 8.2 46 3.6 7.8 47 N.T. N.T. 48
3.7 7.8 49 3.6 8.2 50 4 N.T. 51 N.T. N.T. 52 3.6 N.T. 53 3.7 8.5 54
3.4 8.1 55 N.T. N.T. 56 4 7.7 57 3.1 N.T. 58 3.3 8.0 59 3.3 7.9 60
3.8 8.1 61 3.6 N.T. 62 3.9 8.0 63 3.5 8.0 64 3.7 7.8 65 3.3 7.9 66
3.2 7.8 67 N.T. N.T. 68 N.T. N.T. 69 N.T. N.T. 70 N.T. N.T. 71 N.T.
N.T. 72 N.T. N.T. 73 3.5 8.0 74 3.2 7.7 75 3.6 N.T. 76 3.2 8.0 77
3.4 8.1 78 N.T. N.T. 79 N.T. N.T. 80a 3.9 N.T. 80b 3.9 N.T. 81 3.2
7.8 82 3.8 8.3 83 4.2 8.1 84 3.8 8.1 85 2.9 N.T. 86 3.9 8.0 87 3.9
8.0 88 3.2 8.0 89 3.7 7.6 90 N.T. N.T. 91 3.7 N.T. 92 4 N.T. 93
N.T. N.T. 94 4.2 N.T. 95 N.T. N.T. 96 N.T. N.T. 97 N.T. N.T. 98
N.T. N.T. 99 4.1 N.T.
[0703] In Table 3 above, "N.T.," with regard to a DAP score, means
the compound was not taste tested.
[0704] The data in Table 3 above reflect the best DAP score for the
tested concentrations of 0.1 parts per million (ppm), 1 ppm and 10
ppm. The highest concentrations did not always result in the
highest DAP scores.
[0705] Compounds in water with no sodium were also tested. The
compounds in water with no sodium elicited no appreciably
discernable salty taste, even at the 10 ppm concentration (data not
shown).
[0706] DAP score testing results for various pairs of compounds are
presented in FIG. 1 (sodium solution) and FIG. 2 (broth). Certain
combinations were tested twice. For these combinations, two DAP
scores are shown in the tables presented in FIGS. 1-2. As shown in
the results presented in FIGS. 1-2, certain combinations of
compounds can enhance the perception of saltiness. Some
combinations resulted in DAP scores as high as 4.5 in some tests.
See, for example, the combination of compound 83 and 13 in FIG. 1
(sodium solution) and the combination of compound 12 and 18 in FIG.
2 (broth). Such DAP scores may result in a sodium reduction
potential of about 14%. The combinations tested in FIGS. 1-2 are
representative of the combinations that may be used in a food
product to enhance the perception of saltiness or reduce sodium
content. It will be understood that any other suitable combination
of compounds may be employed.
[0707] Additional testing of combinations of pairs of compounds was
performed in sodium solution. The DAP scores from this additional
testing is shown below in Table 4.
TABLE-US-00005 TABLE 4 Activity of a combination of bioactive
compounds in sodium solution Compound 66: Compound 29: Compound 16:
Compound 33: Compound 73: (0.1 ppm) (10 ppm) (1 ppm) (1 ppm) (1
ppm) Compound 83: (1 ppm) 3.7 4.0 3.8 3.6 4.0 Compound 10: (1 ppm)
3.3 3.7 3.8 2.9 3.6 Compound 45: (10 ppm) 3.2 3.3 3.8 3.7 4.2
[0708] In addition, more than two bioactive, taste modulating or
salty taste modulating compounds described herein may be included
in a food product. By way of example, Table 5 below shows DAP
scores obtained from testing sodium solutions and chicken broth
containing a combination of compounds 12, 13 and 83. As shown in
Table 5, such a combination resulted in a DAP score of 5.3 when
tested in a sodium solution. Accordingly, such a combination may
result in a sodium reduction potential of about 22%. Of course,
other suitable combinations of three or more compounds may be used
or included in a food product to enhance the perception of
saltiness or to reduce sodium content.
TABLE-US-00006 TABLE 5 Activity of a combination of bioactive
compounds in sodium solution and broth In Na In Compound Conc.
Solution Broth 12 1 ppm 5.3 8.1 13 10 ppm 83 1 ppm
[0709] Some illustrative examples of combinations of compounds that
may produce desired or beneficial effect, for example when
incorporated in a food product, include combinations that include
at least one compound selected from the group consisting of
compounds 3, 10, 12, 13, 16, 18, 29, 33, 36, 37, 41, 43, 44, 45,
48, 53, 56, 62, 66, 73, 82, 83, and 84. Another illustrative
example is a combination that includes at least one compound
selected from the group consisting of compounds 10, 12, 13, 18, 36,
45, 56, 82, and 83. Yet another illustrative example is a
combination that includes compounds 12, 13 and 83. Of course, any
other suitable or desirable combination may be used.
[0710] DAP scores for combinations of three different compounds in
broth are shown in Table 6 below.
TABLE-US-00007 TABLE 6 Activity of a combination of bioactive
compounds in broth Compound (concentration) DAP score 3 (0.1 ppm)
7.8 36 (0.1 ppm) 44 (10 ppm) 3 (0.1 ppm) 7.7 36 (0.1 ppm) 53 (1
ppm) 3 (0.1 ppm) 7.9 36 (0.1 ppm) 18 (10 ppm) 13 (10 ppm) 8.1 84 (1
ppm) 44 (10 ppm) 13 (10 ppm) 7.9 84 (1 ppm) 53 (1 ppm) 13 (10 ppm)
8.0 84 (1 ppm) 3 (0.1 ppm) 18 (10 ppm) 8.1 12 (1 ppm) 44 (10 ppm)
18 (10 ppm) 8.2 12 (1 ppm) 53 (1 ppm) 18 (10 ppm) 8.3 12 (1 ppm) 3
(0.1 ppm)
[0711] Sourcing
[0712] Natural sources of the mentioned taste modulating or salty
taste modulating compounds can be extracted by a variety of methods
such as, but not exclusive to, water, solvent extractions
(ethanol/water combinations), or supercritical carbon dioxide or
other volatilization methods. These concentrated extracts or
isolates could be stabilized physically by encapsulation, for
example, or chemical reaction to non-reactive compounds such as
simple sugars or small chain fatty acids. Compounds may be altered
for their solubility in aqueous solutions by hybridization to
larger sized molecules and additionally processed or reacted to
create an impacting ingredient in either a dry or aqueous form.
[0713] In embodiments, a composition comprises a bioactive, taste
modulating or salty taste modulating compound described herein. The
composition may be included in a food product. In embodiments, the
composition comprises one or more natural extracts. In another
embodiment, the extract is selected from a plant or microbial
(e.g., fungi or bacterial) source. Examples of suitable natural
extracts include extracts derived from Aesculus hippocastaneum;
Alchemilla xanthochlora; Angelica archangelica; Apocynum
cannabinum; Azadirachta indica; Actinomycete bacteria (Strain code:
01702axxx000002); Capsicum annuum; Cimicifuga racemosa; Commiphora
mukul; Embelia ribes; Evodia rutaecarpa; Ferula assa-foetida; Fungi
(Strain code: 02295fxxx000001; Strain code: 01469fxxx000005);
Gleditschia australis; Kaempferia galanga; Lavandula officinalis;
Marrubium vulgare; Mesua ferrea; Nephelium cuspidatum; Orthosiphon
stamineus; Persea gratissima; Petroselinum stativum; Piper longum;
Pithecoctenium echinatum; Podophyllum peltatum; Psidium guajava;
Ricinus communis; Salvia miltiorrhiza; Schisandea chinensis; Teclea
trichocarpa; Vitex agnus; Xysmalobium undulatum; Yucca gloriosa;
Zanthoxylum piperitum; Zingiber officinalis and others. The
composition may be in a dry or liquid form. The liquid composition
may be a solution, suspension, colloidal suspension,
microencapsulated suspension, emulsion, or the like, or
combinations thereof. The dry composition may be a
microencapsulation solid, agglomeration, or the like or
combinations thereof.
[0714] In embodiments, a bioactive, taste modulating or salty taste
modulating compound described herein is included in a composition
comprising a carrier. The composition comprising the carrier may be
incorporated into a food product. Any suitable carrier may be used.
Examples of suitable carriers include propylene glycol, ethanol,
water, or oil. In embodiments, the carrier is a starch, such as a
starch comprising carbohydrate, a maltodextrin, a cyclodextrin or
another dextrin, or a liposome. In embodiments, the carrier is an
encaspulant or the carrier may comprise an embedded bioactive,
taste modulating or salty taste modulating compound.
Definitions
[0715] All scientific and technical terms used herein have meanings
commonly used in the art unless otherwise specified. The
definitions provided herein are to facilitate understanding of
certain terms used frequently herein and are not meant to limit the
scope of the present disclosure.
[0716] As used in this specification and the appended claims, the
singular forms "a", "an", and "the" encompass embodiments having
plural referents, unless the content clearly dictates
otherwise.
[0717] As used in this specification and the appended claims, the
term "or" is generally employed in its sense including "and/or"
unless the content clearly dictates otherwise. The term "and/or"
means one or all of the listed elements or a combination of any two
or more of the listed elements.
[0718] As used herein, "have", "having", "include", "including",
"comprise", "comprising" or the like are used in their open ended
sense, and generally mean "including, but not limited to". It will
be understood that "consisting essentially of", "consisting of",
and the like are subsumed in "comprising" and the like. As used
herein, "consisting essentially of," as it relates to an
composition, product, method or the like, means that the components
of the composition, product, method or the like are limited to the
enumerated components and any other components that do not
materially affect the basic and novel characteristic(s) of the
composition, product, method or the like.
[0719] The words "preferred" and "preferably" refer to embodiments
of the invention that may afford certain benefits, under certain
circumstances. However, other embodiments may also be preferred,
under the same or other circumstances. Furthermore, the recitation
of one or more preferred embodiments does not imply that other
embodiments are not useful, and is not intended to exclude other
embodiments from the scope of the disclosure, including the
claims.
[0720] Also herein, the recitations of numerical ranges by
endpoints include all numbers subsumed within that range (e.g., 1
to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, 5, etc. or 10 or less
includes 10, 9.4, 7.6, 5, 4.3, 2.9, 1.62, 0.3, etc.). Where a range
of values is "up to" a particular value, that value is included
within the range.
[0721] As used herein, a "bioactive compound" is a compound that
alters the flow of ions through one or more channels associated
with the perception of salty taste or another taste associated with
consumption of sodium chloride.
[0722] As used herein, a "taste modulating compound" is a compound
that modifies the taste of a food product. By way of example, a
taste modulating compound may modify the taste of a food product
due to a particular taste imparted by the taste modulating
compound, due to a modification of the perceived taste of the food
product, or a component thereof, or the like. In embodiments, a
taste modulating compound is a salty taste modulating compound.
[0723] As used herein a "salty taste modulating compound" is a
compound that, when ingested, elicits or enhances a perception of
salty taste alone or in the presence of a salt, such as sodium
chloride.
[0724] As used herein, a composition that is "substantially
similar" to another composition contains substantially the same
concentration of components (e.g., within about 5%) except for the
specifically enumerated components that make the compositions
different. For example, a composition that includes a salty
compound may be substantially similar to a composition that does
not have the salty compound, if the components of the compositions,
other than the salt and the salty compound, are present in a
substantially similar concentration.
[0725] As used herein, a compound "derived" from a natural product
is a compound that exists in a natural product, whose identity is
verified. The compound derived from the natural product may be
extracted from, for example, a plant or microbial source as opposed
to being produced synthetically. Extraction or isolation of the
naturally-derived compound may be facilitated by simple chemical
reactions such as acidification, basification, ion exchange,
hydrolysis, and salt formation as well as microbial fermentation,
and the like. In embodiments, a taste modulating or salty taste
modulating compound is derived from natural sources such as natural
plant, fungi, and bacterial sources. Examples of such natural
sources include, but are not limited to Aesculus hippocastaneum;
Alchemilla xanthochlora; Angelica archangelica; Apocynum
cannabinum; Azadirachta indica; Actinomycete bacteria (Strain code:
01702axxx000002); Capsicum annuum; Cimicifuga racemosa; Commiphora
mukul; Embelia ribes; Evodia rutaecarpa; Ferula assa-foetida; Fungi
(Strain code: 02295fxxx000001; Strain code: 01469fxxx000005);
Gleditschia australis; Kaempferia galanga; Lavandula officinalis;
Marrubium vulgare; Mesua ferrea; Nephelium cuspidatum; Orthosiphon
stamineus; Persea gratissima; Petroselinum stativum; Piper longum;
Pithecoctenium echinatum; Podophyllum peltatum; Psidium guajava;
Ricinus communis; Salvia miltiorrhiza; Schisandea chinensis; Teclea
trichocarpa; Vitex agnus; Xysmalobium undulatum; Yucca gloriosa;
Zanthoxylum piperitum; Zingiber officinalis; and others. In
embodiments, one or more compounds derived from Persea gratissima
are combined with one or more compounds derived from Kaempferia
galanga or one or more compounds derived from Capsicum annuum; and
others.
[0726] As used herein, an "isolated" or "purified" compound is a
compound that is substantially separated from other components of
the source of the compound. For example, if the source of the
compound is a natural product, an isolated or purified compound may
be a compound that is separated from its naturally occurring
environment. If the compound is synthesized, the compound may be
separated from unreacted reagents, reaction byproducts, solvents,
or the like.
[0727] As used herein a "synthetic compound" is a compound that is
synthesized via chemical reaction in vitro. A compound that is
"synthesized" is a synthetic compound. A synthesized compound may
be identical to a compound derived from a natural product.
[0728] For the purposes of this disclosure, reference to a compound
includes reference to salts of the compound, hydrates of the
compound, polymorphs of the compound, isomers of the compound
(including constitutional isomers and stereoisomers such as
enantiomers and diasteriomers), and the like.
[0729] For the purposes of the present disclosure, it will be
understood that a ring structure having a structure of
##STR00190##
or the like, will be considered to be aromatic.
[0730] It will be understood that compounds disclosed herein may be
glycosylated or may be substituted with one or more saccharides. In
various embodiments, specific or generic compounds substituted with
one or more saccharides are disclosed. However, it will be
understood that other saccharide substitutions are possible and are
contemplated.
[0731] As used herein, a "saccharide" is a monosaccharide or an
oligosaccharide. A monosaccharide may be a diose, a triose, a
tetrose, a pentose, a hexose, a heptose, and so one. Monosacharides
include aldoses and ketoses. Examples of monosaccharides include
glyceraldehyde, dihydroxyacetone, erythrose, threose, erythrulose,
arabinose, lyxose, ribose, xylose, ribulose, xylulose, allose,
altrose, galactose, glucose, gulose, idose, nannose, talose,
fructose, psicose, sorbose, tagatose, mannoheptulose,
sedoheptulose, 2-keto-3-deoxy-manno-actonate, and sialose.
Monosaccharides may be acyclic or cyclic. Cyclic isomers include
furanoses and pyranoses.
[0732] As used herein, "monosaccharide" includes deoxygenated
variants of monosaccharides that are deoxygenated at one or more
positions. As used herein, "monosaccharide" includes
monosaccharides having carbon atoms of a monosaccharide chain or
ring that are substituted with one or more of the following: H(H),
CH.sub.2OH, OH, COOH, OCOR.sup.100, CH.sub.3, OCH.sub.3,
C(CH.sub.3).sub.2OH, and
##STR00191##
where R.sup.100 is selected from the group consisting of
##STR00192##
[0733] An "oligosaccharide" is a chain of two or more
monosaccharides where each monosaccharide is bound by a glycosidic
bond.
[0734] As used herein, "saccharidyl" means a monosaccharide or
oligosaccharide substituent. The monosaccharide or oligosaccharide
substituent may be a terminal substituent or an internal
substituent. That is, a saccharidyl group may be bound to one or
more parent compounds (e.g., parent structure 1-saccharidyl or
parent structure 1-saccharidyl-parent structure 2).
[0735] For purposes of example, a generic structure representing a
monosaccharide is presented below:
##STR00193##
where one of A', B', D', E', F' and G' is O and where each of the
rest of A', B', D', E', F' and G' is independently selected from
the group consisting of CH.sub.2, CHOH, CHCH.sub.2OH, CHCH.sub.3,
CHCOOH, CHOCOR.sup.101, CHOCH.sub.3, CHC(CH.sub.3).sub.2OH, and
##STR00194##
where R.sup.101 is selected from the group consisting of
##STR00195##
[0736] For purposes of Example, a generic structure representing an
embodiment of an oligosaccharide that is a disaccharide is
presented below:
##STR00196##
(i) where (a) one of A', B', D', E', and F' is O, (b) one of A'',
B'', D'', E'', and F'' is O, and (c) each of the rest of A', B',
D', E', F', A'', B'', D'', E'', and F'' is independently selected
from the group consisting of CH.sub.2, CHOH, CHCH.sub.2OH,
CHCH.sub.3, CHCOOH, CHOCOR.sup.102, CHOCH.sub.3,
CHC(CH.sub.3).sub.2OH, and
##STR00197##
where R.sup.102 is selected from the group consisting of
##STR00198##
and (ii) where x' and y' are independently selected from zero or 1.
Typically, the oxygen heteroatom of a monosaccharide ring will be
in an ortho or meta position relative to a saccharide
substitution.
[0737] For purposes of example, a generic structure representing an
embodiment of an oligosaccharide that is a trisaccharide is
presented below:
##STR00199##
[0738] (i) where (a) one of A''', B''', C''', E''', and F''' is O,
(b) one of A'', B'', D'', E'', and F'' is O, and (c) each of the
rest of A', B', D', A'', B'', D'', E'', F'', A''', B''', D''',
E''', and F''' is independently selected from the group consisting
of CH.sub.2, CHOH, CHCH.sub.2OH, CHCH.sub.3, CHCOOH,
CHOCOR.sup.103, CHOCH.sub.3, CHC(CH.sub.3).sub.2O H, and
##STR00200##
where R.sup.103 is selected from the group consisting of
##STR00201##
and (ii) where f', g', x' and y' are independently selected from
zero or 1. In the structure depicted above, the oxygen heteroatom
of a monosaccharide ring is in an ortho position relative to the
other saccharide substitutions. Of course, trisaccharides (or
tetra-, penta-, etc-saccharides) where the where substitutions of
the other saccharides are ortho/meta, ortho/para, meta/para or
meta/meta relative to the oxygen of the central ring are also
possible. Typically, trisaccharides (or tetra-, penta-,
etc-saccharides) will be ortho/ortho, meta/meta, or ortho/meta
regarding the saccharide substitutions relative to the oxygen
heteroatom of a central ring.
[0739] For purposes of example, a generic structure representing an
embodiment of an oligosaccharide that is a tetrasaccharide is
presented below:
##STR00202##
[0740] (i) where (a) one of A''', B''', D''', E''', and F''' is O,
(b) one of A''', B''', D''', E''', and F''' is O, (c) one of A'',
B'', D'', E'', and F'' is O, and (d) each of the rest of A', B',
A'', B'', D'', E'', F'', A''', B''', D''', E''', F''', A'''',
B'''', D'''', E'''', and F'''' is independently selected from the
group consisting of CH.sub.2, CHOH, CHCH.sub.2OH, CHCH.sub.3,
CHCOOH, CHOCOR.sup.104, CHOCH.sub.3, CHC(CH.sub.3).sub.2OH, and
##STR00203##
where R.sup.104 is selected from the group consisting of
##STR00204##
and (ii) where f', g', p', q', x' and y' are independently selected
from zero or 1. In the structure depicted above, the oxygen
heteroatom of a monosaccharide ring is in an ortho position
relative to the other saccharide substitutions. The example of a
tetrasaccharide depicted below is a branched chain saccharide.
However, tetrasaccharides (or penta-, hexa, etc-saccharides) may
have linear chains.
[0741] It will be understood that the structures of the saccharides
presented above are examples of saccharides and that other
saccharides are contemplated herein. Any compound described herein
may be optionally saccharidyl substituted at any suitable position.
Examples of some saccharidyl substituents are presented herein
below (e.g., with regard to compounds 34-39, 41, 48, 51, 76, 77,
and 90-92). However, it will be understood that similar compounds
with different saccharide substitutions are contemplated
herein.
INCORPORATION BY REFERENCE
[0742] Any patent or non-patent literature cited herein is hereby
incorporated herein by reference in its entirety to the extent that
it does not conflict with the disclosure presented herein.
[0743] In the detailed description above several specific
embodiments of compounds, compositions, products and methods are
disclosed. It is to be understood that other embodiments are
contemplated and may be made without departing from the scope or
spirit of the present disclosure. The detailed description,
therefore, is not to be taken in a limiting sense.
* * * * *